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A pharmacokinetic study of prilocaine hydrochloride
in human volunteers was performed. The total body
clearance of this drug was found to be greatly in excess
of values reported for other amide type local anaesthetics
and also to be in excess of human liver blood flow. An
extra-hepatic site for prilocaine metabolism has been
proposed and the possible site of this metabolism was
investigated.
In vitro incubation experiments using lung and
kidney slices from dogs and rabbits were performed. The
results confirmed other reports that both tissues were
capable of metabolising prilocaine, and in greater
quantities than lignocaine.
Experiments with isolated perfused rat lung
3
preparations showed that after equilibration with H
3
lignocaine and H prilocaine in the perfusion medium,
prilocaine was removed from the perfusate to a greater
extent than lignocaine. In further experiments with
isolated perfused rat lungs, utilising a single pass
bolus injection technique, prilocaine was retained in the
lung tissue to a greater degree than lignocaine.
The pharmacokinetics of prilocaine in anaesthetised
dogs was investigated. After infusing prilocaine to
steady state blood concentrations, simultaneous sampling
of blood from the pulmonary artery, through a Swan-Ganz
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catheter, and from the aorta was undertaken. Drug analysis
of these samples showed a small decrease in prilocaine
concentrations from the pulmonary artery to the aorta in two
preparations. Total body clearance of prilocaine in dogs
was found to equal hepatic blood flow. The validity of
the pharmacokinetic model used for analysis was tested
using computer predicted drug concentration data and found
to be correct. Direct determination of the hepatic
extraction of prilocaine in dogs confirmed that hepatic
metabolism was not totally responsible for the clearance
of this drug.
The pharmacokinetics of prilocaine in anaesthetised
rabbits were also investigated and again, total body
clearance of the drug was found to equal hepatic blood
flow. A similar study with anaesthetised anephric rabbits
showed both an increase and decrease in clearance in
different preparations. These differing results have been
attributed to surgical trauma.
Experiments to observe the first pass buffering
effect of the lung on a bolus injection of a prilocaine
and lignocaine mixture in anaesthetised human subjects
was undertaken. The human lung was shown to markedly
reduce the possible peak concentrations of both drugs,
prilocaine concentrations being reduced to a greater
degree than lignocaine concentrations.
The implications of these results with respect to
distribution, metabolism and toxicity of amide type




The concept of the use of local anaesthetics in
clinical practice is generally attributed to Roller (1884)
who used cocaine (Fig 1) for topical anaesthesia of the
eye. New techniques in local anaesthesia followed and by
1900 cocaine had been used for peripheral nerve blockade
and spinal anaesthesia. The occurrence of severe toxic
side effects and the addictive nature of this drug led to
the search for synthetic compounds with local anaesthetic
properties to replace cocaine.
The development of benzoic acid ester derivatives
in the early 1900s, eg procaine and benzocaine (Fig 1),
was a major step forward in improving the safety and
clinical usefulness of local anaesthetics. However, a
major disadvantage of these drugs was their poor chemical
stability in solution. These compounds were also capable
of producing unwanted side effects and generally had a
short duration of activity.
In 1943, Lofgren developed lignocaine (Fig 1), an
amide derivative of diethylamino acetic acid. Although
preceded by the introduction of cinchocaine (Fig 1), a
quinoline derivative, the development of lignocaine was
to lead to the production of a new family of amide type
local anaesthetics (Fig 1). These drugs proved to be
more stable than the ester type local anaesthetics and
generally had a longer duration of activity.
FIGURE 1

































Prilocaine, synthesized by Lofgren & Tegner (1960)
was found to have local anaesthetic qualities similar to
those of lignocaine but to have a lower toxicity
(Weidling, 1960; Xstrom & Persson, 1961). The main
structural differences between prilocaine and lignocaine
are that prilocaine is a secondary amine whereas ligno¬
caine is a tertiary amine, and lignocaine is a xylidine
derivative whereas prilocaine is a toluidine derivative.
Mepivacaine and bupivacaine are characterised by their
amine group being incorporated into a ring system and
etidocaine by its ethyl group on the intermediate chain
of the molecule.
This group of compounds display different local
anaesthetic properties and therefore they have different
clinical applications. Prilocaine, lignocaine and mepi¬
vacaine are generally classified as being local anaes¬
thetics of intermediate potency and bupivacaine and etido¬
caine as local anaesthetics of high potency. The onset
of anaesthesia tends to occur more rapidly with the
intermediate potency drugs than with the high potency
drugs but the latter group usually exhibit a longer
duration of action (Covino & Vassallo, 1976).
There are several factors which affect both the
time to onset and the duration of local anaesthesia.
With subcutaneous infiltration techniques the onset of
sensory anaesthesia is almost immediate, whereas in
peripheral and central nerve blocks the onset of
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anaesthesia may take several minutes, eg 10-15 min for
lignocaine and 15-25 min for bupivacaine in epidural
anaesthesia (in Lund et al, 1975). The longest latency
to onset of anaesthesia occurs with peripheral nerve
blocks involving large nerves, eg brachial plexus block,
and these differences are related to the speed of drug
penetration to the site of action.
An increase in the amount of drug administered tends
to reduce the onset time and increase the duration of
anaesthesia. The duration of local anaesthesia with these
different anaesthetic techniques can depend on the blood
flow through the region of anaesthesia, which effectively
governs the rate at which the drug is removed from the
site of action. The addition of vasoconstrictors to local
anaesthetic solutions increases the duration of most nerve
blocks; the agent most commonly used being adrenaline in
a 1:200,000 dilution. Vasoconstriction decreases the rate
at which the circulation removes the local anaesthetic
from the site of action and hence drug remains at the site
of injection for a longer time.
Of the amide type local anaesthetics, lignocaine has
been most extensively investigated as it has not only been
used as a local anaesthetic but has also been given intra¬
venously for the treatment of cardiac arrhythmias
occurring during myocardial infarction.
Initial studies on the toxicology, mode of action
and fate of lignocaine in the body were summarised by
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Weidling (1964). The toxic effects of lignocaine and the
other amide type local anaesthetics have been well
documented (Scott et al, 1973; Usubiaga et al, 1966;
Scott, 1975) and reviewed (Fink, 1973; Covino & Vassallo,
1976).
Initial symptoms are subjective, with numbness of
the tongue and circumoral numbness occurring due to high
tissue concentrations of drugs in these very vascular
areas, followed by a feeling of lightheadedness or
dizziness, tinnitus and visual disturbances due to mild
central nervous system effects. Objective symptoms are
slurred speech and muscular twitching. High doses may
cause convulsions and eventually respiratory arrest.
The resulting hypoxia and acidosis caused by apnoea occur
very rapidly during convulsions because the muscles are
using large quantities of oxygen (Moore et al, 1980).
This leads to myocardial depression followed eventually
by cardiac arrest.
These toxic effects occur infrequently in general
use of local anaesthetics and usually result from
inadvertent intravenous or intra-arterial injection
(Tucker & Mather, 1979). For certain purposes local
anaesthetics are injected directly into a vein. In
Bier's block, for example, the application of an arterial
tourniquet is used to stop blood circulation in the limb
that is to be anaesthetised, following which local
anaesthetic injected intravenously into the limb will
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produce anaesthesia as long as the tourniquet is applied.
By the time the tourniquet is released, a high proportion
of the injected drug will have been absorbed by the limb
tissues and only a proportion will be released into the
general circulation. However, if the tourniquet is
released prematurely, toxic amounts of local anaesthetic
may gain access to the circulation. Lignocaine is
frequently administered intravenously as a cardiac anti¬
arrhythmic and, under conditions of reduced cardiac out¬
put, toxic concentrations of this drug may occur (Prescott
et al, 1976; Thompson et al, 1971).
While intravascular injection is the commonest
cause of toxicity, severe reactions do occur occasionally
during regional anaesthesia and there are a number of
factors which influence this toxicity. The most important
are the site of injection, the addition of vaso¬
constrictors, the acid/base status of the patient, the
drug used and the hepatic blood flow. The highest blood
concentrations of local anaesthetics are found after
injection into highly vascular regions, eg intercostal
block. However, adipose tissue at the site of drug
administration can absorb large quantities of these local
anaesthetics and hence reduce the rate of their release
into the circulation, even in relatively highly vascular
areas, eg the lumbar epidural space. As previously
mentioned, the use of adrenaline as a vasoconstrictor in
local anaesthetic solutions causes a decrease in blood
flow at the site of injection and this too reduces the
8.
rate of release of local anaesthetic into the circulation.
The physiologic status of a subject is an important
factor influencing local anaesthetic toxicity. The acid/
base balance has been shown to have marked effects on
local anaesthetic blood concentrations (Sjostrand &
Widman, 1973) and acidosis, both metabolic and respiratory,
increases the toxicity of these drugs (Englesson, 1974;
Englesson & Grevsten, 1974). The amide type local anaes¬
thetics are prepared as hydrochloride salts for clinical
use and they have pKa values close to the physiological pH
(mepivacaine 7.6, lignocaine 7.7, prilocaine 7.7,
etidocaine 7.7, bupivacaine 8.1; from Covino & Vassallo,
1976). Thus, changes in blood pH will result in
relatively large alterations in the ratio of uncharged to
cationic form of the drug. The form in which these drugs
are most readily absorbed through cell membranes is as
uncharged base, thus, as blood pH falls, more cationic
drug is present in the blood and the amount of drug
available to be absorbed by the tissues is reduced.
Englesson (1974) and Englesson & Grevsten (1974)
concluded that the increased central nervous system
toxicity of local anaesthetics during respiratory acid¬
osis, particularly in the presence of metabolic acidosis,
was due to lowering of the pH of brain tissue, which is
particularly susceptible to increasing pC02 values. This
increases the cationic form of drug in the brain and
hence maintains the blood/brain tissue base concentration
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gradient causing a greater accumulation of local anaes¬
thetic in brain tissue.
The drug used for a local anaesthetic procedure also
has some bearing on toxicity. When administered intra¬
venously, prilocaine is the least toxic of the amide group
of drugs, followed in order of increasing toxicity by
mepivacaine, lignocaine, etidocaine and bupivacaine.
Because etidocaine and bupivacaine are both high potency
local anaesthetics, smaller amounts of these drugs are
used in clinical practice, thus reducing the possibility
of toxic reactions occurring. Although prilocaine is the
least toxic, its metabolic products have been shown to
produce methaemoglobinaemia in man. However, a clinically
significant reduction of the oxygen carrying capacity of
the blood has only been found after administration of very
large doses of this drug (Crawford, 1965; Lund, 1965).
This reaction to prilocaine limits its use when pain
relief by local anaesthesia involves multiple injections
in patients with an already impaired oxygen transport
system. The most appropriate procedures for the use of
this drug would appear to be those requiring a single
dose of less than 600 mg to provide adequate anaesthesia,
eg in a comparison of prilocaine (450 mg), lignocaine
(450 mg), bupivacaine (150 mg) and etidocaine (150 mg)
for brachial plexus block (Wildsmith et al, 1977) , the
quality and duration of anaesthesia with prilocaine and
the low plasma prilocaine concentrations resulting from
this technique, led to the conclusion that prilocaine
was the drug of choice for this procedure.
The main site for metabolism of amide type local
anaesthetics is the liver and it has been shown that
hepatic blood flow is the primary controlling factor in
the clearance of these drugs from the body (Tucker et al,
1977). It is apparent that any situation resulting in
reduced liver blood flow, eg shock involving a reduced
cardiac output, will increase the possibility of a toxic
reaction to local anaesthetic administration.
The amide type local anaesthetics are considered to
be almost totally metabolised before excretion, with only
very small amounts of unchanged drug found in the urine.
Values for urinary excretion of unchanged drug have been
given as 3% for lignocaine (Keenaghan & Boyes, 1972),
less than 1% for prilocaine (Mather, 1972 in Mather &
Tucker, 1978), 1% for mepivacaine (Meffin et al, 1973),
less than 1% for etidocaine (in Mather & Tucker, 1978)
and 1-10% for bupivacaine (in Mather & Tucker, 1978).
The processes involved in the hepatic metabolism
of the local anaesthetics have been reviewed (Hansson,
1971; Boyes, 1975). Lignocaine metabolism has been the
most extensively studied and the major metabolic pathway
of this drug in humans (Fig 2) appears to be by
oxidative N-dealkylation to monoethylglycinexylidide
(MEGX). MEGX undergoes hydrolysis to form 2,6-xylidine
which in turn is hydroxylated to form 4-hydroxy 2,6-
xylidine. MEGX can also be further dealkylated to form
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glycinexylidide (Keenaghan & Boyes, 1972). These meta¬
bolites are then excreted in the urine.
Metabolic studies of prilocaine have been less
extensive. Geddes (1965) demonstrated that prilocaine
could be metabolised by both liver and kidney slices from
the rat and suggested that the initial metabolic step was
hydrolysis of the amide linkage of the parent drug to
o
form o-toluidine and N-propylalanine (Fig 2). Akerman
et al (1966a) confirmed these results with further in
vitro work with tissue from a variety of animals. They
reported that lung tissue, as well as liver and kidney
tissue, were capable of metabolising prilocaine. Further
o
work by Akerman et al (1966b) identified two further
metabolic products in the urine of rats and cats which
were hydroxylation products of o-toluidine. These meta¬
bolites were identified as 2-amino-5-hydroxytoluene and
2-amino-3-hydroxytoluene (Fig 2) which have been implicated
in the occurrence of methaemoglobinaemia after the
administration of prilocaine. Subsequently Akerman &
Ross (1970) demonstrated that the enzyme activity in the
liver responsible for prilocaine hydrolysis in vivo was
located exclusively in the microsome fraction.
Because the toxic effects of the amide type local
anaesthetics are mainly caused by their effect on the
central nervous system, any factor reducing the amount
and rate of these drugs reaching the central nervous
system could assist in reducing toxic reactions to local
FIGURE 2























































anaesthetics. After intravenous injection or absorption
from the site of administration, all the administered
drug must pass through the lungs before reaching the
brain. Englesson & Grevsten (1974) implicated the lungs
as a major site of local anaesthetic distribution in the
body. Tucker & Boas (1971) proposed that uptake of local
anaesthetics by the lung could act as a buffer, by
absorbing large quantities of these drugs, and thereby
protecting the central nervous system by reducing high
and possibly toxic blood concentrations. Also, tissue
o
incubation experiments (Akerman et al, 1966a) have demon¬
strated the possibility of metabolism of prilocaine in
the lung.
The initial interest in non respiratory functions
of lung tissue was stimulated by the work of Starling &
Verney in 1925. They demonstrated rapid vasoconstriction
in isolated perfused kidneys using defibrinated blood,
but when the perfusate used was passed through a heart-
lung preparation, this vasoconstrictor response was lost.
The substance responsible for this action was later
identified as 5-hydroxytryptamine (5-HT) and was shown
to be inactivated by isolated perfused cat lungs (Gaddum
et al, 1953).
Since then much work has been done on the ability
of the lung to absorb and metabolise both endogenous and
exogenous substances and several reviews have been
published (Heinemann & Fishman, 1969; Brown, 1974;
Junod & de Haller, 1975; Junod, 1976; Lofstrom, 1978;
Roth & Wiersma, 1979; Post, 1979).
Studies by Davis & Wang (1965) using simultaneous
injections of indocyanine green and 5-HT showed a 33%
removal of 5-HT by the pulmonary circulation in an intact
dog preparation. However, much of the work on the uptake
and metabolism of drugs by the lung has been performed
with isolated perfused lung preparations. Alabaster &
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Bakhle (1970) found a 92% removal of H-5-HT from perfusate
by isolated perfused rat lungs and reported that most of
the radioactivity recovered in the perfusate was probably
5-hydroxyindoleacetic acid (5-HIAA), a metabolite of 5-HT.
This process was found to be concentration independent in
the concentration range 5-100 ng ml Other workers have
found that removal of 5-HT from these perfusion systems
to be mediated by a sodium dependent transport system
(Junod, 1972b; Pickett et al, 1975; Iwasawa & Gillis,
1974) and that uptake of 5-HT is a saturable process.
Monoamine oxidase has been shown to be responsible for
5-HT deamination by the rabbit lung (Gillis, 1973) but
inhibition of this enzyme did not alter the ability of
the lung to remove 5-HT from the perfusate.
Noradrenaline (NA) has also been shown to be
accumulated by the lung in isolated perfused lung
preparations (Alabaster & Bakhle, 1973; Nicholas et al,
1974; Iwasawa & Gillis, 1974) and, as for 5-HT, this
process is saturable and sodium dependent. However, 5-HT
is taken up to a greater extent than NA (Gillis et al,
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1972; Gillis et al, 1974). The site of uptake of these
two substances has been identified as the pulmonary
capillary endothelial cells (Strum & Junod, 1972; Hughes
et al, 1969).
Various factors have been shown to influence lung
uptake of 5-HT and NA, such as cardiopulmonary bypass
(Gillis et al, 1972; Gillis et al, 1974) after which
extraction of both drugs from the circulation was
increased. This was reported to be due to an increased
surface area in the pulmonary vascular bed, across which
these substances can be transported, caused by an increase
in pulmonary artery pressure and possibly some stimulation
of the active process accumulating 5-HT and NA. Ana¬
phylaxis caused an increase in NA uptake by isolated
guinea pig lung (Mathe & Volicer, 1977) which was
attributed to improved membrane permeability. Conversely,
competition with other drugs, eg imipramine, has been
shown to reduce pulmonary uptake of both 5-HT and NA
(Nicholas et al, 1974; Alabaster & Bakhle, 1970; Junod,
1972b).
Imipramine is a tricyclic antidepressant which
inhibits the presynaptic uptake of NA and 5-HT. Further¬
more, it has been proposed that inhibition of lung uptake
of these substances by imipramine is due to direct
competition for binding sites (Gillis, 1973). Conversely,
Junod (1972a) found that 5-HT did not inhibit lung uptake
of imipramine and suggested that this could be due to
imipramine binding to many more sites than 5-HT. Hence,
it is easier to produce 5-HT uptake inhibition by imi¬
pramine than imipramine uptake by 5-HT. Junod also found
that imipramine was not accumulated by the same sodium
dependent mechanism operating for 5-HT and that the
process was saturable.
Orton et al (1973) investigated lung uptake of a
variety of basic and non-basic drugs by isolated perfused
rabbit lungs and found that 50-95% of the basic drugs
but only 10-20% of the non-basic drugs were accumulated
by the lung tissue. Of the drugs investigated, only
methadone was found to be metabolised by the lung to any
degree. Other drugs which have been shown to be meta¬
bolised by intact lung preparations are propanolol
(Kornhauser et al, 1980), ibuterol (Ryrfeldt & Nilsson,
1978) and mescaline (Roth et al, 1977). More comprehen¬
sive lists of drugs metabolised by the lung can be found
in the reviews of Brown (1974), Post (1979) and Roth &
Wiersma (1979). Comparison of results obtained using
lung tissue or cell fraction incubations with results
obtained from intact lung preparations, regarding drug
metabolism by the lung, have shown wide discrepancies.
Lung homogenates will metabolise imipramine and chlor-
cyclizine but intact perfused lung preparations have
not confirmed these findings (Orton et al, 1973; Law
et al, 1974; Eling et al, 1975). This is probably due
to different cell types and enzymes coming into contact
with these drugs which does not occur in the intact organ.
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The uptake of lignocaine by lung tissue has been
widely investigated. Katz (1968) found 3.2% of the total
dose of lignocaine in the lungs of rats one minute after
intravenous injection. Tucker & Boas (1971), in work on
intravenous regional anaesthesia in humans, recognised the
ability of the lung to absorb large quantities of local
o
anaesthetics. Akerman et al (1966a) found that after
intraperitoneal, intramuscular and subcutaneous injections
of a mixture of lignocaine and prilocaine in rats, the
main difference in distribution to the tissues was in the
lung, where prilocaine was concentrated to a much greater
extent than lignocaine. Similar results were obtained
after intraperitoneal injections of lignocaine and prilo¬
caine in guinea pigs (Hansen et al, 1968 in LofStrom,
1978).
Sjostrand & Widman (1973) studied the effects of
acidosis on the tissue distribution of bupivacaine in
rabbits after a 20 min infusion of this drug. In normal
rabbits they found a tissue : blood bupivacaine concen¬
tration ratio of 8:1, but in acidotic rabbits, much
higher drug concentrations were attained by lung tissue,
giving a ratio of 19.5:1. These workers stated that
these changes could not be solely explained by an increase
in organ blood flow combined with the increase in blood
drug concentration. They suggested that with an increase
in the water soluble form of bupivacaine (ie the cationic
form) in acidotic animals, changes in the properties of
the cellular membrane occurred together with an increase
in tissue affinity for the drug and a combination of these
factors resulted in the higher lung uptake of bupivacaine
in acidosis.
Work on dogs has shown the arterial pH (7.4) to be
greater than the pH of the pulmonary extravascular fluid
(6.7) (Effros & Chinard, 1969) and this would suggest a
mechanism for the accumulation of basic amines in lung
tissue. As the uncharged base enters the extravascular
tissue, it will equilibrate as uncharged base and cation,
but there will be a greater proportion of cation in the
extravascular fluid than in the blood (Fig 3). Hence a
concentration gradient will be maintained between
uncharged base in the blood and uncharged base in the
tissue which will result in a greater concentration of
drug in the pulmonary tissue than in the blood. Effros &
Chinard also stated that after an infusion of 0.4 M
sodium carbonate to produce alkalosis, tissue concentrations
of cationic amines increased and that after an infusion
of 0.3 M hydrochloric acid to produce acidosis, these
concentrations decreased. This is the reverse situation
to that found by Sjostrand & Widman (1973).
In later work, Effros et al (1972) working with
potentially 'anionic' amines (the barbiturates), found
that the distribution of these compounds could not be
fully explained by nonionic diffusion, as they also
accumulated in lung tissue at higher concentrations than
in blood. They concluded that the distribution of weak
FIGURE 3
A MECHANISM FOR THE ACCUMULATION OF A BASIC AMINE (pKa = 7.7)
IN LUNG TISSUE. B = THE UNIONISED FORM OF THE COMPOUND AND
HB = THE IONISED FORM OF THE COMPOUND
BLOOD
pH 7.4
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acids and bases across cellular membranes was governed not
only by the pKa of the substance, but also by the degree
of lipid solubility of the compound and the extent of its
protein binding. Rberg (1972) observed that the L-isomer
of mepivacaine accumulated in lung tissue to a greater
extent than its D-isomer. This stereo specific
accumulation indicates that there may be specific binding
sites and the affinity for these sites is dependent on the
molecular configuration of the drug.
Post et al (1978) demonstrated that lignocaine was
concentrated in rat lung slices by a non energy dependent
process to a level seven times greater than the extra¬
cellular space and suggested that accumulation of ligno¬
caine occurred not only within the cells, but also by
being fixed to the cell surface by passive binding sites.
Feinstein & Paimre (1969) suggested that this binding
process would be by the attachment of the cationic form
of lignocaine to negatively charged sites on the endo¬
thelium of the cells. Post also found that extraction
of lignocaine by intact perfused lungs was biphasic in
nature suggesting two processes of lignocaine
accumulation. This biphasic nature of lung uptake has
also been reported for methadone (Wilson et al, 1976),
propranolol (Dollery & Junod, 1976) and imipramine
(Anderson et al, 1974).
In further work with rat lung slices, Post et al
(1979) demonstrated a greater tissue uptake at pH 8.0 of
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lignocaine, bupivacaine and etidocaine than at pH 7.0 but
could not relate the differences in uptake between these
drugs to their lipid solubility. These workers found that
lignocaine uptake by lung slices could be inhibited by
nortriptyline and that this drug could also displace
lignocaine from isolated perfused rat lungs. This
observation was related to displacement of lignocaine
from easily accessible binding sites on the capillary
endothelium of the lung.
Using a technique involving the simultaneous intra¬
venous injection of indocyanine green (an inert marker)
and lignocaine in anaesthetised pigs (Bertler et al, 1978)
it was demonstrated that 30-40% of lignocaine was absorbed
in a single pass through the lungs. This supports the
theory that the lung can act as a buffer to protect the
central nervous system from high concentrations of local
anaesthetic after intravenous administration. Bertler et
al also showed that the efficiency of this uptake process
decreased as the dose of lignocaine was increased. Using
a similar technique with unanaesthetised human volunteers,
Jorfeldt et al (1979) reported a 64% first pass pulmonary
uptake of lignocaine. They proposed that, because the
removal of lignocaine from the circulation was so rapid,
binding of unionised lignocaine within the lipid part of
the pulmonary endothelial cell membrane and extracellular
binding of the cationic form of lignocaine to negatively
charged sites on the pulmonary endothelial cell surface
were the most likely processes involved in pulmonary
uptake of lignocaine.
It is apparent that the lungs are capable of
absorbing large quantities of local anaesthetic and this
is probably effective in reducing central nervous system
toxicity of these drugs by reducing the blood concen¬
trations reaching the brain. It has been proposed that
the mechanisms involved in the uptake of the amide type
local anaesthetics are intracellular absorption of the
unionised form of the drug and binding of the cationic form
of the drug to negatively charged sites on the pulmonary
endothelial cell surfaces. Any factor altering the ability
of the lung to accumulate these drugs could have an effect
on the dose of local anaesthetic required to produce toxic
symptoms. Such factors include changes in blood and tissue
pH, changes in pulmonary arterial pressure, pulmonary
disease and competition with other drugs.
The main aims of the studies reported in this thesis
were to determine the pharmacokinetics of prilocaine in
man and to assess the role of the lung in the distribution
and metabolism of the amide type local anaesthetics.
SECTION 1
PHARMACOKINETICS OF PRILOCAINE AND
MEPIVACAINE IN HUMAN VOLUNTEERS
PHARMACOKINETICS OF PRILOCAINE AND MEPIVACAINE
IN HUMAN VOLUNTEERS
INTRODUCTION
Of the amide type local anaesthetics, prilocaine is
the only drug which has not been extensively investigated
regarding its pharmacokinetic characteristics. Lignocaine
pharmacokinetics in man have been most widely investigated
(Boyes et al, 1971; Rowland et al, 1971; Benowitz et al,
1974) and recently reviewed (Benowitz & Meister, 1978).
The pharmacokinetics of bupivacaine and mepivacaine were
determined in man by Reynolds (1971) and a comparison of
bupivacaine with etidocaine has been undertaken (Scott et
al, 1973). Lignocaine, mepivacaine, etidocaine and bupi¬
vacaine were studied by Tucker & Mather (1975) and the
results of other workers reviewed. Further reviews have
been published by these authors (Mather & Tucker, 1978;
Tucker & Mather, 1979). Eriksson (1966) and Lund &
Covino (1967) have presented data which suggested a much
greater total body clearance of prilocaine as compared to
lignocaine.
This study was designed to determine the pharmaco¬
kinetic variables of prilocaine and mepivacaine in healthy
male volunteers, using the results obtained for mepi¬
vacaine as a comparison with previously published data.
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MATERIALS AND METHODS
Ten healthy male volunteers (Table 1-1) agreed to
take part in the study, having been fully informed of the
nature of the drugs and the experimental protocol. Five
volunteers received both an infusion of 250 mg prilocaine
hydrochloride and an infusion of 250 mg mepivacaine
hydrochloride on two separate occasions separated by at
least seven days. The other five volunteers received only
the 250 mg prilocaine hydrochloride infusion.
Prilocaine hydrochloride (1% Citanest, Astra
Chemicals Ltd, Watford, GB) or mepivacaine hydrochloride
(2% Carbocaine, Pharmaceutical Manufacturing Co, Bolton,
GB) were diluted with saline to give a 5 mg ml ^ solution.
Each infusion was given over a 12.5 min period into a vein
in the dorsum of the right hand at a rate of 4 ml min
(20 mg min ^") through an indwelling needle (Butterfly,
23-G, Abbot Laboratories Ltd, Kent, GB) using a Harvard
syringe infusion pump (Harvard Apparatus, Millis, Mass,
USA) .
Venous blood samples (5 ml) were withdrawn during
and after the infusion through an indwelling cannula
(Venflon 18-G, 45 mm long, Viggo AB, Helsinborg, Sweden)
and transferred to heparinised tubes (Brunswick, 10 ml
lithium heparin tubes, Sherwood Medical Ltd, Co Antrim,
N Ireland). The samples were centrifuged, the plasma
separated, transferred to plain plasma tubes (Seward




Volunteer (yr) (cm) (kg) Smoker
1 (HB) 33 183 76 No
2 (GD) 32 188 77 No
3 (DF) 28 166 60 No
4 (AN) 31 179 64 No
5 (DL) 32 182 82 Yes
6 (RA) 27 179 72 Yes
7 (JM) 30 175 67 No
8 (RM) 33 178 60 No
9 (GO) 23 171 67 No
10 (BM) 29 175 71 Yes
X 30 178 70
SD 3 6 7
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in a freezer until analysis.
The volunteers who received infusions of prilocaine
hydrochloride and mepivacaine hydrochloride had blood
samples withdrawn at regular intervals for four hours.
Those subjects receiving only the prilocaine infusion had
blood samples withdrawn for eight hours. The electro¬
cardiogram (ECG) was monitored on all occasions for the
first 60 minutes of the experiment and systemic arterial
pressure was monitored by a semi automatic sphygmo¬
manometer (Parama UM-15LN, Parama Co Ltd, (1947) Co,
Blackpool, GB). Plasma drug concentrations were deter¬
mined by a gas liquid chromatographic technique as
described in Appendix 1. The concentrations of both
compounds have been expressed in terms of the drug hydro¬
chloride and throughout this work, unless otherwise stated,
prilocaine hydrochloride is referred to as prilocaine,
mepivacaine hydrochloride as mepivacaine and lignocaine
hydrochloride monohydrate as lignocaine.
Pharmacokinetic analysis of the plasma drug
concentration data was based on a two compartment open
model, details of which are given below.
Pharmacokinetic Analysis Based on a Two Compartment
Open Model
The division of the body into two compartments to
describe the fate of an administered drug is not based
on anatomical considerations. The division is determined
by a mathematical description of the shape of the post-
absorption time/concentration profile as determined by
analysis of blood samples taken at various times after the
administration of the drug. The shape of the time/drug
concentration profile on a semilogarithmic plot (Fig 1-1)
has two distinct phases. These can generally be thought
of as an initial distribution phase during which the drug
blood concentration drops rapidly as it is distributed to,
and absorbed by, the different tissues of the body, followed
by the elimination phase which reflects the loss of drug
from the body either by metabolism or excretion of
unchanged drug.
The mathematical derivations used to describe the two
compartment model here are basically as previously
presented by Gibaldi & Perrier (1975).
The graph in Fig 1-1 represents the result of a
single instantaneous intravenous bolus injection into the
system. The resolution of the curve into its two linear
phases gives two intercept points, A and B, on the
concentration axis and these intercept values can be
related to the blood drug concentration at any time after
the injection of the drug:
Ct = Ae~at + Be~Pt 1
Where = blood drug concentration (i_ig ml ^")
at time (t) after drug injection
a = the slope of the rapid distribution
phase of the drug (min "^)
FIGURE1-1
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3 = the slope of the slower elimination
phase of the drug (min "*")
t = the time (min) after drug injection
A and B = the intercept values (yg ml "*")
The half lives of both the a and 3 phases represent
the time taken for the blood drug concentration to be
halved. These are determined:
Fig 1-2 is a schematic representation of a two
compartment system. The central compartment equilibrates
rapidly and anatomically it is probably represented by
the blood and the highly perfused body tissues such as
the heart, lungs, liver, brain and kidneys. The peri¬
pheral compartment equilibrates slowly and is probably
formed by the less perfused tissues such as muscle and
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k^ an^ k2^ = rate^of transfer between the
two compartments
FIGURE1-2








The rate constants are derived from A, B, a and 6
A3 + Bak
k
21 A + B
a3
10 = k21
As a + 3 = k^2 + ^21 + k10 then
k]_2 a + 3 k21 k1Q
The area under the plasma (or blood) concentration
curve can be both measured (AUCM), using the trapezoidal
rule with correction for infinite time, or calculated
(AUCC):
AUC = — + —AULC a 3
A comparison of AUC^, and AUC^ gives some indication
as to the validity of the calculated variables, ie if
AUC^ and AUCM are very similar then it is probable that
the calculated pharmacokinetic variables are accurate.
The Vc and values are hypothetical volumes
(expressed as litres) of each compartment which
effectively relate to the volume of blood required to
account for the amount of drug in each compartment.
The volume of the central compartment (V ) is
calculated:
V (1) =
c A + B
Where XQ = the initial dose of the drug (mg)
and A and B are as previously defined
To determine V it is necessary to determine the
P
total volume of distribution of the body (V,-.) which is
calculated:
v„- X°B
f— + —} R
a + 3)3
which is the same as:
VB AUC„.3 10
hence V = Vn - V 11
p B c
The pharmacokinetic variable used to relate drug
concentration to the rate of drug elimination is the
clearance value (CI). This relates to the volume of
blood from which all drug is apparently removed in a
certain unit of time and is defined:
-1 x
CI (1 min ) = 12
Throughout the results presented in this work,
C1M represents the value obtained where AUCM has been
used in equation 12 and Clc the value obtained where
AUCC has been used in equation 12.
In Section 4 of this work the term CI has been
ss
used. This term represents the clearance value obtained
from drug concentration data obtained after steady state
concentrations of drug have been reached following an
intravenous infusion. CI is defined:
ss
-l ^
CI (1 min ) = fS— 13
ss
where C = drug concentration at steady state
o o
(yg ml 1)
kQ = rate of infusion (mg min "*")
As mentioned previously, these derivations have been
based on an instantaneous bolus injection of drug. In the
human volunteer study reported here, prilocaine and mepi-
vacaine were infused intravenously over a period of
12.5 minutes and in other experiments reported later, drug
has been infused intravenously over longer time periods.
As a result of this the determined A and B intercept
values from these experiments would not be the same had
the total dose been given as an instantaneous intravenous
bolus injection. These intercept values obtained after
an intravenous infusion have been termed A' and B' and
have been corrected for infusion time using equations
derived by Loo & Riegelman (1970).
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B = ^37 • B1 15
1 - e 31
where t = the infusion time (min)
and the other terms are as previously defined
RESULTS AND DISCUSSION
Heart Rate, Blood Pressure and ECG
There were no significant alterations in heart
rate, blood pressure (Appendix 5) or ECG throughout the
monitoring period.
Prilocaine and Mepivacaine Plasma Concentrations
Appendices 6 and 7
The time/concentration profiles for both drugs are
illustrated in Fig 1-3. As peak plasma concentrations of
the drugs were reached towards the end of the infusion,
one subject receiving prilocaine and two receiving mepi¬
vacaine reported mild toxic symptoms (numbness of the
lips and tongue and feeling light headed). After
terminating the infusion, plasma concentrations of
prilocaine fell very rapidly at first then a slower
decline in concentrations occurred until, at 420 minutes
after the start of the infusion, the plasma concentrations
of prilocaine were less than the minimum detectable limit
of the assay (ie less than 0.05 yg ml ^).
FIGURE1-3
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Pharmacokinetic Analysis
Data derived from the pharmacokinetic analysis of
plasma prilocaine concentrations are shown in Table 1-2.
The calculated and measured area under curve values were
very similar indicating that the calculated data
represented an accurate description of the blood level
results. The half life of elimination of prilocaine was
97 minutes which is similar to the value reported for
lignocaine (96 minutes) by Tucker & Mather (1975). The
total body clearance for prilocaine was calculated to be
2.42 1 min 1 with only two subjects having values less
than 2 1 min It is generally accepted that amide type
local anaesthetics are metabolised almost entirely by the
liver and that only small amounts of the drugs are
excreted unchanged in the urine (Boyes, 1967; Eriksson
o
& Granberg, 1965; Akerman et al, 1966a). Therefore,
clearance values for these drugs must be less than liver
blood flow, which has been reported as ranging from
1.5 1 min (Tucker et al, 1977; Ganong, 1975) to
1.7 1 min (Price et al, 1960). The clearance value of
prilocaine exceeds the highest accepted level of liver
blood flow suggesting that prilocaine is subject to some
extra-hepatic metabolism.
Tucker et al (1977) reported that prolonged
infusions (150 min) of lignocaine, bupivacaine and
etidocaine increased liver blood flow, with a maximum
value of 2.0 1 min 1 obtained for the lignocaine infusion.
TABLE 1-2
PHARMACOKINETIC VARIABLES OF PRILOCAINE IN HUMAN VOLUNTEERS
(mean values ± SD)
X SD
a (min ^") 0.101 0.033
8 (min ^") 0.0079 0.0O29
t'sa (min) 7.5 2.2
t^g (min) 97 30
A (yg ml 1) 3.02 1.99
B (yg ml 1) 0.61 0.22
AUCC (yg ml "*".min ) 108 22
AUC (yg ml "'".min )M 109 26
CI (1 min "S 2.42 0.62
vB (1) 343 130
vc (1) 87 40
Vp (1) 256 105
k1Q (min 1) 0.035 0.019
k21 (min 1) 0.024 0.006
k12 (min 1) 0.062 0.046
The data for each volunteer can be found in Appendix 8
It is possible that the short prilocaine infusion given
in this study (12.5 min) increased the hepatic blood
flow of the volunteers somewhat but probably not enough
to account for the high prilocaine clearance values.
The data of Tucker et al (1977) showed that during the
first 30 minutes of the infusion of lignocaine, bupi-
vacaine and etidocaine there was very little change in
hepatic blood flow. Also, Lalka et al (1976) using a
shorter infusion of lignocaine (8 min) reported no change
in the indocyanine green clearance (a good index of liver
blood flow as this dye is entirely eliminated by the
liver) during the experiment. The mean value for the
volume of distribution of prilocaine was relatively
large (343 1), this being mainly due to the large volume
of distribution of the peripheral compartment (256 1).
The volunteer who experienced toxic symptoms during
the prilocaine infusion (GO) had the lowest clearance
value (1.61 1 min "*") of all ten subjects and also had the
highest peak plasma concentration (5.27 yg ml "*") . With
this same subject plasma prilocaine concentrations
decreased very rapidly after the end of the infusion and
the t^8 of 64 minutes was the second fastest obtained in
this group of volunteers. The volume of distribution in
this subject was relatively small (148 1) compared to the
mean value of 343 1.
Table 1-3 gives some of the pharmacokinetic data
for prilocaine and mepivacaine from this work and
TABLE1-3
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provides a comparison with pharmacokinetic data for
mepivacaine and other local anaesthetics presented by
Tucker & Mather (1975). It is apparent that the two sets
of mepivacaine results are similar, implying that the
high clearance value obtained for prilocaine in this
study was not due to the volunteers having unusually high
liver blood flows. The clearance value of prilocaine is
twice that of etidocaine, the only other of these drugs
with a clearance value in excess of 1 1 min ^. Although
prilocaine has a low lipid solubility (Covino & Vassallo,
1976) it has a relatively large volume of distribution.
The only amide type local anaesthetic with a larger
volume of distribution is etidocaine and it is over 100
times more lipid soluble than prilocaine.
SKF 525A, an inhibitor of oxidative metabolism,
was found to inhibit lignocaine but not prilocaine
o
metabolism (Akerman et al, 1966a) indicating that prilo¬
caine, unlike lignocaine, does not undergo oxidative
degradation as a first step in its metabolism. Geddes
(1965) and Akerman et al (1966a) suggested that the
primary metabolic pathway of prilocaine was by hydrolysis
of the amide bond, forming o-toluidine and N-propyl-
alanine with further hydroxylation products identified by
o
Akerman et al (1966b) (Fig 1-4). The amidase enzyme
responsible was believed to be present not only in the
liver, but also in the lung and kidney. In later work,
Rkerman & Ross (1970) reported that the enzyme activity
in the liver, responsible for the hydrolysis of prilocaine,
FIGURE 1-4
METABOLIC PATHWAY OF PRILOCAINE
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was located in the microsome fraction and that this system
had the same pH dependency as reported for the hydrolysis
of the lignocaine metabolite monoethylglycinexylidide
(Hollunger, 1960b) and suggested that the two fractions
o
were identical. Work by Akerman et al (1966a) using
slices and homogenates of lung and kidney from rabbits
and cats demonstrated that both these tissues were capable
of metabolising prilocaine to a similar degree. Geddes
(1965) also reported that kidney slices from rats
metabolised prilocaine. However, the calculated minimum
extra-hepatic clearance of over 700 ml min 1 observed in
this study represents 50-60% of the renal blood flow but
only 10-15% of pulmonary blood flow, hence the lungs
seemed to be the more attractive organ to propose as a
site of extra-hepatic metabolism.
The following experiments were designed in an
attempt to identify the extra-hepatic site of prilocaine
metabolism and elucidate the contribution of the lungs
to the distribution of local anaesthetics in the body.
SECTION 2
LUNG UPTAKE OF PRILOCAINE AND
LIGNOCAINE BY RAT LUNG PREPARATIONS
34.
ISOLATED PERFUSED RAT LUNG PREPARATIONS
INTRODUCTION
In vivo studies on the tissue distribution of
o
lignocaine and prilocaine in rats (Akerman et al, 1966a)
showed that prilocaine was found to be accumulated to a
much greater extent in the lung than lignocaine.
Post et al (1978) found the uptake of lignocaine
by rat lung slices to be dependent on the pH of the
incubation medium and Englesson & Grevsten (1974)
recognised the effect blood pH could have on the uptake
and distribution of local anaesthetics.
The following experiments were designed to quantify
the lung uptake of lignocaine and prilocaine by an
isolated perfused rat lung preparation and to observe any
changes in this uptake at perfusate pH values at the
extremes of physiological tolerance.
MATERIALS AND METHODS
The lung preparation and perfusion system was
basically that described by Ryrfeldt & Nilsson (1978).
Male Sprague-Dawley rats weighing between 250 and 300 g
were used in these experiments. Heparin (500 IU) was
injected into a tail vein of the rat, then the animal
was anaesthetised with pentobarbitone sodium (20-40 mg)
given intraperitoneally. A tracheotomy was performed
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and then the thorax opened by a midline incision to reveal
the heart and lungs. The circulatory system was drained
through an incision in the right ventricle and through
this incision the pulmonary artery was catheterised using
a short length (approximately 5 cm) of silastic tubing,
care being taken to avoid the introduction of air bubbles
into the system. An incision was then made in the left
ventricle and the pulmonary venous return catheterised
with a similar length of silastic tubing via the left
ventricle and left atrium. Both catheters were firmly
sutured to prevent leakage of perfusate from the system.
The lung and heart were then cut free from the animal and
suspended in an artificial thoracic chamber. The
pulmonary artery catheter was connected to the perfusate
reservoir and the pulmonary venous catheter connected to
the outflow port of the chamber (Fig 2-1). The lungs
were ventilated with warmed humidified carbogen
(95% C>2/5% CC>2) using alternating negative pressure
(-5 to -50 mm water) created by an animal respirator
(Harvard Rodent Respirator, Model 681, Harvard Apparatus,
Millis, Mass, USA). The lungs were perfused with Kreb's-
Ringer bicarbonate buffer (Appendix 10) containing 4.5%
bovine albumin (Fraction V, Sigma, Poole, Dorset, GB)
and 0.1% glucose. The perfusate was maintained within
the pH range 7.35 to 7.40 for most experiments, countering
the tendency of the pH to rise by intermittently blowing
carbon dioxide into the perfusate reservoir. The pH of
the perfusion medium was changed to the ranges 7.00 to
FIGURE 2-1
DIAGRAMMATIC REPRESENTATION OF THE ISOLATED PERFUSED RAT LUNG SYSTEM
a. stirrer i. vacuum pump
b. perfusate reservoir j. peristaltic pump
c. pressure manometer k. respirator
d. thoracic chamber 1. lung
e. electromagnetic flowmeter m. pulmonary arterial
f. sampling port catheter
g. pH/pO^ electrodes n. pulmonary venous
h. perfusate reservoir catheter
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7.05 and 7.80 to 7.85 for some experiments; lowering the
pH by bubbling carbon dioxide through the perfusate and
increasing the pH by the addition of small amounts of 0.1
molar sodium hydroxide solution.. The pH and p02 were
constantly monitored using pH and p©2 electrodes in a
flow cell (Radiometer, Copenhagen) built into the perfusion
system. The system was maintained at a temperature of 37°C
by a system of circulating warmed water jackets. The
perfusate flow rate was monitored using an electromagnetic
flowmeter and was adjusted to 15 ml min by raising or
lowering the height of the perfusate reservoir. Further¬
more, control experiments were also run with no lungs in
the system, using the same perfusion conditions as listed
above, to determine to what extent the drugs were
adsorbed by the tubing in the system.
After the lung had equilibrated in the system, ie
after the perfusate flow, pH and p02 had stabilised, a
250 y1 bolus injection of the tritiated drug was intro¬
duced into the system through a rubber union between the
perfusate reservoir and the pulmonary artery catheter.
Samples of perfusate were then withdrawn from a sampling
port in the system at the following times after drug
injection: 0, 1, 1.5, 2, 2.5, 3, 5, 7, 9, 11, 13, 15,
17, 19, 21, 25, 30 minutes. The recirculating perfusion
system contained an initial volume of approximately 62 ml
(including the 250 yl injection and the dead space of
3
the catheters and lungs). H-lignocaine hydrochloride
-1 3
(specific activity 37.5 yCi mg ) and H-prilocaine
hydrochloride (specific activity 29.12 yCi mg "*") (Astra
Lakemedel AB, Sodertalje, Sweden) were dissolved in
distilled water at concentrations of 650 yg ml and
657 yg ml ^ respectively. Thus a 250 yl injection would
produce perfusate lignocaine and prilocaine concentrations
of approximately 2.6 and 2.7 yg ml ^ respectively,
assuming that uniform mixing and no absorption of the
drugs were to occur.
To a 100 yl sample of perfusate 10 ml of a
scintillation cocktail (Instagel, Packard, HP Svierge AB,
Lund, Sweden) was added and sample radioactivity was
assayed using a liquid scintillation spectrometer
(Packard Tri-Carb 2425). Each sample was counted three
times for a period of four minutes and the mean
disintegrations per minute (dpm) calculated by a computer
programmed to automatically compensate for quenching
effect.
Lung tissue was homogenised in distilled water and
weighed samples oxidised using a Packard Tri-Carb Sample
Oxidiser (Model 306). The radioactive residue was mixed
with 15 ml of a scintillation cocktail (Monophase,
Packard) and each sample counted three times for a period
of four minutes then the mean dpm calculated as previously
described. The efficiency of the oxidation system was
determined by running lung homogenate samples of known
activity through the same procedure as for the unknown




The amount of drug in each sample has been expressed
as a percentage of the expected drug concentration in a
theoretical perfusate sample taken from the system at
equilibrium with no absorption of the drug occurring.
These values were calculated from the relationship:
. drug in sample - th^Tt!cTdpm *
It should be noted that if any metabolism of either drug
occurred in this preparation then radioactivity associated
with the metabolites would be included in these results.
Post et al (1978), using a similar rat lung
14
perfusion system, found that C-lignocaine disappeared
from the perfusion medium when the lung was excluded from
the system. Control experiments indicated that the mean
drug loss from the perfusate with no lung in the system
was 11% for both lignocaine and prilocaine and the data
quoted for lung uptake of these drugs has been
appropriately corrected.
With both the lignocaine and prilocaine experiments,
an equilibrium was attained in the system by five minutes
(Fig 2-2). With lignocaine in the system, at physiologic
pH (range 7.35 to 7.40) a mean amount of 9% (using data
from 5-30 min) of the drug was removed from the perfusate
and for prilocaine this was 18% (Table 2-1). The
difference between the amounts of lignocaine and prilo¬
caine remaining in the system at equilibrium was
FIGURE 2-2
MEAN % OF THE DOSE OF PRILOCAINE AND LIGNOCAINE REMAINING IN RAT LUNG
PERFUSATE AT TIMES UP TO 30 min AFTER DRUG INJECTION INTO THE
ISOLATED PERFUSED RAT LUNG SYSTEM. THE PLOTTED VALUES HAVE BEEN
CORRECTED FOR CONTROL EXPRIMENTAL DATA. ( SE bars are too small to









AMOUNT OF DRUG IN PERFUSATE EXPRESSED AS A % OF EXPECTED
CONCENTRATIONS AT EQUILIBRIUM. THE DATA HAS BEEN CORRECTED
FOR DRUG LOSS FROM THE PERFUSATE IN CONTROL EXPERIMENTS






























































X 90 94 94 93 94 93 93 92 92 92 91
Using Student's t test for two means, the results for
lignocaine in the pH range 7.35-7.40 (5-30 minutes) were
significantly greater than those for prilocaine (p <0.001)
statistically significant (p <0.001).
This difference was reflected by the results of
the analysis of lung tissue (Table 2-2) with prilocaine
concentrations (19.67 yg g "*") twice those of lignocaine
(9.71 yg g 1) .
The observed lung uptake of lignocaine and prilo¬
caine from this in vitro work is in agreement with the
in vivo experiments of £ke rman et al (1966a) who, using
rats, found that after intramuscular injections of both
drugs, concentrations of prilocaine in lung tissue were
much greater than those of lignocaine. This difference
in lung uptake is however difficult to explain. Both
drugs have the same pKa value (7.7; from Covino &
Vassallo, 1976) so in the given pH range both drugs would
be present in the same proportions of uncharged base and
charged cation and hence equally available for tissue
absorption. Of the two drugs, lignocaine is the more
lipid soluble (Covino & Vassallo, 1976) suggesting that
lignocaine should be more readily taken up by lung tissue.
Prilocaine, however, is bound to plasma protein to a
lesser degree than lignocaine (55% and 64% respectively;
from Covino & Vassallo, 1976) so, assuming that both
drugs are similarly bound to bovine serum albumin, more
prilocaine than lignocaine would be unbound and available
for lung absorption in greater amounts than lignocaine.
This does not however adequately explain the two-fold
difference in lung uptake of the two drugs.
TABLE2-2




















Thedifferencebetwe nlignocain(pH7.35—*7.40)a dprilo ainewas statisticallysign ficant(p<0.001,Student'seforwome ns)
40.
Using a lung slice incubation technique, Post et al
(1979) showed that in rat lung slices lignocaine was
accumulated to a greater extent at a pH of 8 than at
normal pH (7.4) or acid pH (7.00). They proposed that
this was due to greater amounts of local anaesthetic base
existing at alkaline pH, which is much more lipid soluble
than the cationic form of the drug and hence is more
readily absorbed by lung tissue. However, Sjostrand &
Widman (1973), using an in vivo technique, demonstrated
that acidotic rabbits attained bupivacaine levels in lung
tissue five times greater than in normal rabbits. This
they attributed to changes in the physical properties of
tissue bound receptor sites, causing an increase in the
affinity for bupivacaine. In this study, changing the
perfusate pH from normal range (7.35 to 7.40) to both
acidotic (7.00 to 7.05) and alkalotic (7.80 to 7.85)
produced no perceptible changes of lignocaine concen¬
trations in the perfusion medium (Table 2-1). Also there
was little difference in the tissue drug concentrations
(Table 2-2).
Feinstein & Paimre (1969) proposed that negatively
charged groups on phospholipids and proteins of endo¬
thelial membranes could be responsible for the binding
of the cationic form of local anaesthetics. So with the
perfused lung preparation described here it is possible
that at acid pH, less lignocaine base was absorbed by
the tissue than at normal pH, but more was bound to the
negative binding sites of the endothelial membranes and
vice versa at alkaline pH.
However, as only two preparations were run at each
extreme of pH, no firm conclusion can be made from these
results.
IN SITU PERFUSED RAT LUNG PREPARATIONS
INTRODUCTION
The previous experiments with isolated perfused rat
lungs indicated the extent of lung uptake of lignocaine
and prilocaine at steady state perfusate concentration.
However, these results gave little indication of the
ability of lung tissue to remove these drugs from the
circulation in a single passage through the pulmonary
vascular bed.
These experiments were designed to observe the
effect on instantaneous bolus injections of a mixture of
lignocaine and prilocaine in a single pass through the
pulmonary vascular bed, to determine if the process of
absorption was saturable and to see how these drugs
effluxed from the lung.
MATERIALS AND METHODS
Male Sprague-Dawley rats weighing approximately
300 g were anaesthetised with approximately 40 mg
pentobarbitone sodium given intraperitoneally and then
the circulatory system heparinised by administering
500 IU heparin into a tail vein. A tracheotomy was
performed on the animal by inserting a 4 cm length of
polyethylene tubing into the trachea through a neck
incision. A further incision was made in the abdomen
of the rat and the aorta cut to kill the animal. The
thorax was then opened to expose the heart and lungs.
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Polyethylene tubing was used to catheterise the pulmonary
artery via an incision in the right ventricle and the
pulmonary venous return collected through a similar
catheter introduced into the left atrium via an incision
in the left ventricle. Both catheters were firmly
sutured into position to prevent leakage of perfusion
medium from the system. The lungs were perfused with
Tyrodes buffer (Appendix 11) containing 4% bovine serum
albumin (Fraction V, Sigma, Poole, Dorset, GB) and 0.1%
glucose, since this was found to have a more stable pH
under the conditions of this experiment than Kreb's
buffer as used in the previous experiment.
The perfusion medium was adjusted to pH 7.35-7.40
at the start of the experiment using 0.1 molar hydro¬
chloric acid or 0.1 molar sodium hydroxide as required
and the pH was checked at the end of the experiment to
ensure that no large fluctuations had occurred during the
perfusion period. The lungs were partially inflated,
the tracheotomy tube clamped and the perfusion flow
adjusted to approximately 10 ml min ^ by altering the
height of the perfusate reservoir. Perfusion flow was
determined by measuring the perfusate volume collected
over a 30 second period. The perfusate and the preparation
were maintained at approximately 37°C by warming both with
a 60 watt light bulb.
The injection solutions were prepared by weighing
out the appropriate amount of prilocaine hydrochloride
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(Citanest, Astra Pharmaceutical Products Inc, Worcester,
Mass, USA) and lignocaine hydrochloride monohydrate
(Xylotox, Pharmaceutical Manufacturing Co, Bolton, GB)
and dissolving the mixed drugs in less than 0.5 ml
absolute ethanol (AR Grade, James Burrough Ltd, London,
GB) then further diluting these solutions with distilled
water. The same injection solution was used throughout
all experiments at each concentration. Aliquots of each
injection solution were assayed to verify their drug
content.
Bolus injection of 10 yl drug solution (containing
either 10, 50, 150, 250 or 1,000 yg of both drugs) into
the system was achieved by inserting the needle of a
10 microlitre Hamilton syringe (Microliter No 701, Dyson
Instruments, Durham, GB) through a rubber union connecting
the pulmonary artery catheter to the perfusate reservoir.
The injection was made over a period of less than one
second.
The pulmonary venous outflow was collected
continuously as 2 ml samples for ten samples then three
further 10 ml samples were collected. Samples were
analysed for lignocaine hydrochloride monohydrate and
prilocaine hydrochloride by a gas liquid chromatographic
technique as described in Appendix 1.
Experiments were also performed with just the two
catheters joined together with perfusate flowing through
the system to see if the catheters contributed to the
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uptake of drug by the system.
RESULTS AND DISCUSSION
Perfusate Drug Concentration Data
At all doses, except the 1 mg dose, the perfusate
concentrations of lignocaine were significantly greater
than those of prilocaine for the initial samples
(Table 2-3). The lignocaine concentrations then dropped
more rapidly than the prilocaine concentrations (Fig 2-3)
and the prilocaine concentrations became significantly
greater than those of lignocaine until the end of the
sampling period (Table 2-3). The drug concentration data
in Fig 2-3 has been plotted at the mid-point volume of
each sample as is appropriate for this type of sample
collection and analysis.
The total amounts of each drug recovered by the
end of the sampling period were calculated and have been
expressed as a percentage of the initial dose (Table 2-4).
There was a tendency with the 10 yg, 50 yg and 150 yg
injections for lignocaine recoveries to be greater than
for prilocaine. This tendency was reversed with the
250 yg and 1 mg injections. However, the difference
between recoveries was only statistically significant
with the 10 yg injection (p <0.001).
TABLE2-3
MEANPERFUSATEDRUGCONCENTR IONATA±SD


















































































































































































































































































































































Statisticaldifferencesbetweenlignocainedp locai econc ntrations(S ude t'spa dst) t=p<0.05P. 1*<O OOl
FIGURE 2-3
INDIVIDUAL SEMILOGARITHMIC PLOTS OF MEAN PRILOCAINE AND LIGNOCAINE
PERFUSATE CONCENTRATIONS .v. VOLUME OF PERFUSATE PASSING THROUGH RAT
LUNGS, AFTER THE SIMULTANEOUS INJECTION OF EQUAL AMOUNTS OF EACH DRUG.
( Statistical analysis of the data is given in Table 2-3)
perfusate volume (ml) perfusate volume (ml)
perfusate volume (ml)
TABLE 2-4
% DRUG RECOVERED IN
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Statistical analysis was by Student's paired t test
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Pharmacokinetic Analysis
The semilogarithmic plot of drug concentration and
perfusate volume can be likened to a plot of urinary
excretion data where a semilogarithmic plot of excretion
rate versus time is usually made. In this case, the time
factor has been replaced by a volume factor and as a
result of this, the excretion rate (usually expressed as
amount of drug excreted per unit of time) becomes
perfusate drug concentration, ie amount of drug 'excreted'
per unit of volume.
The perfusate concentration data from the 10 yg and
50 yg doses was found to have two components of efflux
from the lung and the other doses were shown to be
composed of three components (Fig 2-4). Because the x
axis of the graph has been expressed as a volume, the
half lives of the different phases have been expressed in
millilitres, ie the volume of perfusate passing through
the lung for the concentration of drug in the effluent
perfusate to be halved (Vh) . The terms for the slopes
of these phases have accordingly been changed to milli¬
litres ^.
In all experiments, the first concentration data
points (0-2 ml) were not included in the analysis as
these samples contained the dead volume of the catheters
and lungs, resulting in spurious drug concentration data.
The a phase of drug efflux from the lung (150 yg,
FIGURE2-4


































250 yg and 1 mg doses only) was probably due to drug
passing through the lungs unaffected by tissue binding
or uptake. The V^a values were very similar for both
drugs (Table 2-5) with all values less than 1 ml.
The remaining two phases were attributed to two
different sites of drug uptake in the lung tissue. Post
et al (1978), in a study of lung extraction of lidocaine
by isolated perfused rat lungs, have proposed at least
two compartments of lignocaine uptake. Similarly, work
with propranolol (Hayes & Cooper, 1971) has produced
evidence for at least two types of binding site in rat
lung, one having a high affinity for the drug and the
other a low affinity for the drug.
The 8 and y phases were probably related to two
sites of drug uptake in the lung tissue, one site
releasing the drugs back to the perfusate at a slower
rate than the other.
Although the mean V^8 values for prilocaine were
greater than those for lignocaine at all doses except
the 1 mg dose there was no statistical difference
between these values. The V^y values for prilocaine
were greater than those for lignocaine at all doses and
were significantly greater for the 50, 150 and 250 yg
doses.
In studies with imipramine, amphetamine, chlor-
cyclizine and methadone, Anderson et al (1974), using
TABLE2-5



























































































































*p<0.05forthedifferencebetw nprilocaineand lignocainedata(Student'stesforwome n )
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an isolated perfused rabbit lung preparation, found the
accumulation of basic amines in lung tissue to be
dependent on the steady state blood concentration of the
drug. They also found the accumulation of the drugs to
be biphasic with a saturable and nonsaturable component.
In this study, V%8 and V^y values increased with dose up
to the 150 yg dose, the values thereafter all being very
similar (Table 2-5). This data suggests that at a dose
between 50 and 150 yg there is some saturation of the
uptake sites of these two drugs. However, the fact that
the terminal phase drug concentrations increase with dose
indicates that the drug uptake in this phase is dose
dependent. These results could be interpreted as the
site of uptake for the y phase being intracellular
absorption of the unionised form of the drug and that
the 8 component could be related to extracellular
binding of the cationic form of the drug to negatively
charged binding sites of the endothelial cell membranes.
SECTION 3
METABOLISM OF PRILOCAINE AND LIGNOCAINE
BY KIDNEY AND LUNG SLICE PREPARATIONS
49.
LUNG AND KIDNEY TISSUE INCUBATIONS
WITH LIGNOCAINE AND PRILOCAINE
INTRODUCTION
Metabolism of prilocaine by rat kidney slices was
demonstrated by Geddes (1965). Akerman et al (1966a)
found that both kidney and lung slices from cats and
rabbits were capable of prilocaine metabolism but had
little effect on lignocaine.
In the human volunteer study (Section 1) it had
been proposed that the lung, and possibly the kidneys,
could be the site of extra-hepatic clearance of prilo¬
caine. These experiments were designed to determine the
ability of lung and kidney slices from two species of
animal, dog and rabbit, used in work described later in
this thesis, to metabolise both lignocaine and prilo¬
caine .
MATERIALS AND METHODS
Lung and kidney samples were obtained from New
Zealand White rabbits and mongrel dogs. Once the tissues
were removed they were placed on ice and incubations were
started within 45 minutes.
Slices of tissue, 1-2 mm thick, were cut from the
main piece of tissue using a scalpel. Three slices of
each tissue, weighing approximately 2 g for kidney
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samples and 1 g for lung samples, were placed in separate
weighed plastic 50 ml containers with screw cap lids. To
each flask was added 10 ml of oxygenated Kreb's buffer
(Appendix 10) with 0.1% glucose added which had previously
been adjusted to a pH of 7.40. There were three
incubation periods of 0, 30 and 60 minutes with one
container for each incubation period.
Lignocaine and prilocaine were introduced to the
tissue samples by two methods. In three of the five
rabbit tissue preparations, and one of the four dog tissue
preparations, an intravenous injection of a mixture of the
two drugs was given prior to sacrificing the animal and
removing the required tissue. With the remaining tissue
preparations, a mixture of the two drugs in aqueous
solution was added to the incubation medium at the start
of the incubation period. Using the latter technique, the
resultant concentration of the drugs in the system was
approximately 10 |ig ml .
As a control, 1 ml of 1 molar hydrochloric acid was
immediately added to the first flask of each set of three
and these were frozen. The lids of the other two flasks
of each set were sealed and these placed in a water bath
with a reciprocal shaker at 37°C. After 30 minutes in
the water bath, the second flask in each series was
removed and 1 ml of 1 molar hydrochloric acid added to
each and the flasks placed in a freezer. The same pro¬
cedure was repeated with the remaining flasks after a
total incubation period of 60 minutes.
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At a later date, the flasks were removed from the
freezer and allowed to thaw. The flasks and contents were
then reweighed to determine the total weight of the
incubation medium plus tissue. The contents of the flasks
were homogenised for a period of one minute (Ultra-Turrax,
Scottish Scientific Instruments, Kingsknowe, Edinburgh,
GB) and aliquots of the homogenate analysed for lignocaine
and prilocaine content, using a gas liquid chromatographic
technique adapted from the method described for rat lung
perfusate in Appendix 1.
Flasks containing drug and incubation medium, but no
tissue, were run through the same procedure as described
above to act as control samples to monitor the effect of
the incubation process on drug concentrations.
RESULTS AND DISCUSSION
The results have been expressed as the percentage of
drug remaining in the samples after the incubation period
and have been corrected for the tissue content of each
sample.
With tissue removed from animals injected with local
anaesthetic prior to organ removal there appeared to be a
tendency for a higher percentage of drug metabolism. This
however could have been due to the fact that the overall
sample drug concentrations with these preparations was
less than those of the preparations to which drug was
added to the incubation medium. Kidney samples of both
species were unable to metabolise lignocaine but had a
small capability for prilocaine metabolism (Fig 3-1).
Rabbit lung slices appeared to metabolise both
prilocaine and lignocaine to the same extent, but dog
lung slices appeared to have a greater ability to
metabolise prilocaine compared to lignocaine (Fig 3-1) .
Blank incubations, with no tissue in the perfusate/drug
mixture, showed no loss of either drug from the system
over the 60 minute incubation period.
These results are similar to those obtained by
o
Akerman et al (1966a) in that both studies showed that
rabbit lung slices were capable of metabolising prilocaine.
However, unlike the data presented here, they did not
observe any metabolism of lignocaine by rabbit lung slices.
The data from rabbit kidney slice incubations obtained
o
here was in agreement with the results of Akerman et al,
except that the rabbit kidney slice incubation data
presented here showed a lower capability for prilocaine
metabolism. Geddes (1965) had also demonstrated prilo¬
caine metabolism by rat kidney slice incubation.
o
Akerman et al also used cat tissue for their incub¬
ation studies. Cat lung and kidney tissue slices were found
to be capable of metabolising both prilocaine and lignocaine,
although prilocaine was metabolised to a greater extent
than lignocaine in both tissues. In the present study,
dog lung tissue was used and shown to metabolise more
FIGURE 3-1
GRAPHS TO ILLUSTRATE THE AMOUNTS OF PRILOCAINE AND LIGNOCAINE
METABOLISED BY LUNG AND KIDNEY TISSUE SLICES FROM RABBITS AND DOGS



















time (min) time (min)
A -Prilocaine #-Lignocaine
prilocaine than lignocaine while kidney tissue, although
capable of some prilocaine metabolism, showed no ligno¬
caine metabolism. Post et al (1978) had been unable to
14
find any metabolism of C-lignocaine by rat lung slice
incubations.
Care should be taken however in placing too much
importance in these results as other workers have reported
that lung tissue preparations have been capable of chlor-
cyclizine and imipramine metabolism but this has not been
true for intact perfused lung preparations (Orton et al,
1973; Law et al, 1974; Eling et al, 1975). The reason
for this is probably due to the large number of different
cell types in the lung, many of which will not absorb
large quantities of drug from the blood in an intact lung,
and it may well be that enzymes released from these cells
by slicing or homogenising are the cause of some drug
metabolism.
However, the data from these lung and kidney slice
incubations suggested that perhaps the lung was the most
likely place to look for extra-hepatic metabolism of
prilocaine.
SECTION 4
PULMONARY EXTRACTION, HEPATIC EXTRACTION
AND PHARMACOKINETICS OF PRILOCAINE
IN THE ANAESTHETISED DOG
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PHARMACOKINETICS AND PULMONARY EXTRACTION
OF PRILOCAINE IN DOGS
INTRODUCTION
In the pharmacokinetic study of prilocaine in human
volunteers, it was proposed that the lung may be a site
of extra-hepatic metabolism of prilocaine.
The work with isolated perfused rat lungs showed a
significant lung uptake of prilocaine. Furthermore, the
in vitro experiments with lung slice preparations demon¬
strated prilocaine was metabolised by lung tissue,
o
confirming the results obtained by Akerman et al (1966a).
This experiment was designed to describe the
pharmacokinetics of prilocaine in the dog and to determine
to what extent pulmonary metabolism contributed to the
total body clearance of this drug.
MATERIALS AND METHODS
The Animals and Anaesthesia
Six mongrel dogs in the weight range 9.5 - 18.0 kg
(Centre for Laboratory Animals, Bush Estate, Edinburgh,
GB) were used in this experiment. The animals were fasted
overnight, premedicated with promazine (2 mg) and atropine
(0.6 mg) given intramuscularly (approximately 1 hr before
induction of anaesthesia), then anaesthetised with
pentobarbitone sodium given intravenously (approximately
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25 mg kg-"*") . Endotracheal intubation was performed and
anaesthesia maintained by spontaneous respiration of a
mixture of nitrous oxide (3 1 min 1) and oxygen
(1 1 min "*") through an open anaesthetic circuit.
The Preparation
A catheter was inserted into the right femoral
artery to monitor arterial blood pressure, using a
Sanborn transducer (Hewlett Packard Ltd, South Queens-
ferry, West Lothian, GB) giving both a calibrated visual
display and chart recording. The arterial blood pressure
and the heart rate were determined from the chart
recording. The left carotid artery was exposed by an
incision in the neck and a catheter passed through the
artery into the aortic arch for the withdrawal of blood
samples. In the first three dogs it was hoped to obtain
mixed central venous blood samples from a catheter passed
through the right jugular vein and into the right atrium.
In the last three dogs, this method was improved by using
a Swan-Ganz catheter (American Hospital Supply (UK) Ltd,
Didcot, Oxon, GB) introduced by the same route and
positioned in the pulmonary artery using blood pressure
tracing to verify its position.
A vein in the right forepaw of the animal (right
cephalic vein) was cannulated (Medicut, 18 G, Sherwood
Medical Industries, Ballymoney, Co Antrim, N Ireland)
for the infusion of prilocaine hydrochloride (Citanest,
Astra Pharmaceuticals Inc, Worcester, Mass, USA).
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All catheters, unless otherwise stated, were
prepared from Portex manometer tubing (Portex Ltd, Hythe,
Kent, GB) and the two sampling catheters were designed to
have the same dead volume. The correct positioning of
all the catheters was verified by autopsy at the end of
each experiment.
The Infusion
All six dogs received a 100 minute infusion of a
prilocaine hydrochloride solution estimated to obtain a
steady state blood concentration of approximately
2 yg ml ^ using the formula:
= Css * VB
= the rate of delivery of drug into the
system (mg min kg "*") ;
= the steady state concentration of prilocaine
hydrochloride (yg ml 1);
= the slope of the elimination phase of the
drug (min ^);
= the total volume of distribution of the
drug (1 kg "*")
Pharmacokinetic data (3 and Vg) from the human
volunteer study (see Table 1-2) was substituted in the
above equation to give an approximation of the infusion
rate kQ. The resulting infusion rate was 0.075 mg min ^






used would weigh approximately 20 kg, an infusion rate of
1.6 mg min ^ was chosen. As the predicted time to reach
steady state blood concentrations with a constant rate
infusion was over 7.5 hours (5 x t%3, using the t^3
value from the human volunteer study) a loading infusion
of approximately 40% of the total dose was given to reduce
the time to reach reasonably constant blood concentrations
to 60 minutes.
A solution of prilocaine (5 mg ml was diluted to
a concentration of 4 mg ml 1 with Hartmann's Solution
(Compound Sodium Lactate Injection BP, Travenol
Laboratories Ltd, Thetford, Norfolk, GB) and infused
through the cannula in the right cephalic vein using a
Harvard syringe infusion pump (Harvard Apparatus, Millis,
Mass, USA) at a rate of 1 ml min (4 mg min "*") for
20 minutes then 0.4 ml min ^ (1.6 mg min ^) for a further
80 minutes to give a total infusion volume of 52 ml
containing 208 mg prilocaine hydrochloride.
The Samples
In all experiments, blood samples were withdrawn
simultaneously from the aortic and the right atrial/
pulmonary artery catheters at regular intervals both
during and after the drug infusion (Table 4-1). The
technique involved withdrawing blood in excess of the
dead volume of the catheters then using new syringes to
withdraw each 3 ml sample. The dead volume blood was
then returned to the preparation through the sampling
TABLE 4-1
EXPERIMENTAL PROCEDURE AND SAMPLING TIMES
Anaesthesia and catheter
insertion
-45 min —» 0 min
Prilocaine hydrochloride
infusion
O —► 20 min at 4 mg min ^ ^
20 —* lOO min at 1.6 mg min
Blood samples
(both sampling sites)
0, 20, 40, 60, 62, 64, 66,
68, 70, 72, 76, 78, 80, 82,
84, 86, 88, 90, 95, 100, 102,
104, 106, 108, 110, 115, 120,
130, 145, 160, 190, 220, 250,
280 min
Blood gases 0, 60, lOO, 130, 220 min
Halothane 1.5%
(dogs 1 and 2 only)
75 —> 87 min
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catheters and these were flushed with 3 ml heparinised
Hartmann's solution (10 units heparin ml "*") to replace
blood loss and to keep the catheters patent.
The blood samples were transferred to 10 ml plastic
lithium heparin tubes (Brunswick, Sherwood Medical Ltd,
Ballymoney, Co Antrim, N Ireland) and refrigerated until
assayed for whole blood prilocaine hydrochloride content
using a GLC technique described in Appendix 1.
Blood samples were also withdrawn at regular inter¬
vals from the aortic catheter into heparinised glass
syringes for blood gas analysis (Corning 175 Automatic
pH/blood gas System, Halstead, Essex, GB).
In dogs 1 and 2, 1.5% halothane (Fluothane, ICI
Pharmaceuticals, Macclesfield, Cheshire, GB) was added to
the nitrous oxide/oxygen mixture during the infusion
period (75-85 minutes) to see what effect the addition of
a volatile anaesthetic gas would have on prilocaine blood
concentrations.
The whole blood prilocaine concentration data was
subjected to pharmacokinetic analysis on the basis of a
two compartment open model as described previously
(see Section 1) and statistical analysis of the results
was carried out using Student's t test for paired and
unpaired data where appropriate.
RESULTS AND DISCUSSION
Heart Rate, Blood Pressure and Blood Gases
Appendices 12 and 13
During the 100 minutes of the infusion the heart
rate was virtually unchanged being 159 beat min ^ at the
start of the infusion, 150 beat min ^ at the end of the
infusion and 142 beat min ^ 120 minutes after the end of
the infusion.
No remarkable changes in blood pressure were
observed throughout the experiments except during the
period of halothane administration in dogs 1 and 2 where
a decrease in both diastolic and systolic pressures were
observed. In these two animals, blood pressure returned
to normal shortly after the termination of the halothane
administration.
Blood gas analysis showed that all the dogs were
acidotic and hypercarbic for the duration of the
experiments compared to normal values (from Feigl &
d'Alecy, 1972; Appendix 13), as would be expected in
spontaneously breathing anaesthetised animals. However,
all animals maintained a fairly constant blood gas
status through the course of each experiment.
Prilocaine Blood Concentration Data
For dogs 1, 2 and 3, the prilocaine blood
concentration data obtained from right atrial samples
were found to be erratic. When the areas under the
curves were measured, the AUCM for the aorta sample data
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of dog 2 was much greater than the value for the right
atrial data with the reverse situation occurring with
dog 3 (Table 4-2). With the other preparations the
AUC^ values were very similar. It is probable that the
differences in the results for dogs 2 and 3 were due to
incomplete mixing of venous blood in the right atrium.
Because of this, it was decided to exclude the pharmaco¬
kinetic data obtained from dogs 1, 2 and 3.
For dogs 4, 5 and 6 in which mixed venous blood
was sampled from a Swan-Ganz catheter in the pulmonary
artery, the mixed venous and arterial prilocaine concen¬
tration/time profiles were found to be very similar
(Fig 4-1). However, the mixed venous concentrations were
statistically significantly higher than the arterial
concentrations at steady state in dogs 4 and 6 (Table 4-3).
With dog 5, the steady state concentrations at both
sampling sites were almost identical. From the prilocaine
concentration data in Table 4-3 it is apparent that the
drug concentrations continued to rise slowly between
60-100 minutes, ie absolute steady state concentrations
(C ) had not been attained. This is further reflected byss u
a comparison of the mean Csg values and the predicted Cgs
values (Table 4-4) obtained using the formula:
The prilocaine concentrations at 100 minutes (Table 4-4)
had, however, almost reached the predicted C values.s s
TABLE 4-2
comparison of auc values for both arterial and
m
mixed venous prilocaine concentration data
1 2
Preparation
3 4 5 6
aucm
Arterial 352 382 521 538 364 468
-1
(pg ml . min ) Mixed 333 241 772 539 370 467
Venous
FIGURE 4-1
INDIVIDUAL SEMILOGARITHMIC PLOTS OF PRILOCAINE
BLOOD CONCENTRATION .v. TIME FOR DOGS 4, 5 & 6
X = arterial concentrations











STEADY STATE PRILOCAINE HYDROCHLORIDE CONCENTRATIONS
AT STEADY STATE (60-100 MIN) FOR DOGS 4, 5 AND 6
(yg ml-1)
TIME
DOG 4 DOG 5 DOG 6
(min)
ART MV ART MV ART MV
60 3.39 3.52 2.25 2.26 2.92 2.81
62 3.45 3.52 2.18 2.22 2.68 3.17
64 3.48 3.48 2.18 2.24 2.95 2.57
66 3.60 3.69 2.27 2.19 2.97 2.76
68 3.59 3.57 2.18 2.27 2.86 2.87
70 3.61 3.68 2.27 2.24 2.80 3.45
72 3.68 3.69 2.26 2.28 2.88 2.61
76 3.72 3.74 2.24 2.30 2.73 2.95
78 3.76 3.82 2.27 2.22 2.98 2.89
80 3.85 3.80 X 2.30 3.02 2.95
82 3.92 3.91 2.26 2.39 2.87 3.09
84 X 3.91 2.37 2.25 2.99 3.06
86 3.84 3.80 2.31 2.22 3.00 3.39
88 3.89 3.92 2.35 2.25 3.00 3.30
90 3.90 3.86 2.27 2.23 2.91 3.64
95 3.94 4.04 2.35 2.38 3.18 3.78
loo 4.05 4.08 2.47 2.39 3.44 3.57
X 3.72 3.78 2.28 2.27 2.95 3.11
SD 0.20 0.18 0.08 0.06 0.17 0.36
P <0.05 NS <0.05
ART = Arterial concentrations
MV = Mixed venous concentrations
X = No sample obtained
Statistical analysis was by Student's paired t test
TABLE 4-4
COMPARISON OF THE PREDICTED AND MEAN Csg VALUES
AND C AT lOO MINUTES (THE END OF THE INFUSION)
OF PRILOCAINE HYDROCHLORIDE (pg ml"l)
DOG 4 DOG 5 DOG 6
ART MV ART MV ART MV
Predicted C__
ss
4.14 4.14 2.80 2. 80 3.60 3.60
Mean Cgs 3.72 3.78 2.28 2.27 2.95 3.11
C at lOO min 4.05 4.08 2.47 2.39 3.44 3.57
ART = Arterial concentrations
MV = Mixed venous concentrations
After terminating the infusion, arterial prilocaine
concentrations were consistently greater than mixed venous
concentrations in these three preparations (Table 4-5).
This was probably due to prilocaine, taken up by the lung
tissue during the infusion, returning to the circulation
from the lung tissue to maintain the tissue/blood
equilibrium as prilocaine was removed from the body by
metabolism.
Returning to the data for dogs 1 and 2, the intro¬
duction of halothane (1.5%) to the anaesthetic gas
mixture caused both arterial and right atrial prilocaine
concentrations to rise (Appendix 14). Hughes et al
(1980) demonstrated that 2% halothane reduced the total
hepatic blood flow in the dog by 40% as well as reducing
the cardiac output. These factors would lead to a
reduced clearance of drugs metabolised by the liver and
would account for the increases in prilocaine blood
concentrations found here.
Pharmacokinetic Analysis
The pharmacokinetic analysis of the prilocaine
concentration data was based on a two compartment open
model as described in Section 1. Because the infusion
was given at two different rates, it was not possible
to determine the corrected A and B intercept values
using the equations of Loo & Riegelman (1970), as the
rate of the infusion is not taken into account with
this method. The derivation of the equations used to
TABLE 4-5
POST INFUSION WHOLE BLOOD PRILOCAINE CONCENTRATION DATA
(yg ml-1)
TIME
DOG 4 DOG 5 DOG 6
(min)
ART MV ART MV ART MV
102 2.80 2.60 2.18 2.17 2.29 2.17
104 2.49 2.32 1.82 1.66 2.02 1.95
106 2.27 2.16 1.49 1.46 1.86 1.77
108 2.07 2.00 1.35 1.30 1.70 1.65
110 1.96 1.87 1.26 1.23 1.58 1.56
115 1.62 1.57 1.08 1.01 1.37 1.33
120 1.43 1.42 0.90 0.87 1.23 1.18
130 1.19 1.17 O.72 O.70 1.03 0.98
145 0.94 O.94 0.59 0.55 0.82 0.79
170 O.79 O.78 0.49 0.46 0.71 0.65
190 0.60 0.58 0.39 0.38 0.50 0. 50
220 0.48 0.49 O.33 0.33 0.42 0.40
P <0.01 <0.01 <0.001
ART = Arterial concentrations
MV = Mixed venous concentrations
p values for difference between ART
and MV (Student's paired t test)
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determine these values is now given.
Derivation of A and B Intercept Values for an Infusion
Given at Two Rates
In the method shown here, the kinetics of each
infusion rate have been considered separately and the
resultant formulae have been derived from a summation
of the characteristics of the two separate infusions.
Fig 4-2a represents an actual concentration/time
profile resulting from the combined infusion and Fig 4-2b
represents the separated time/concentration profiles for
the two infusions superimposed on the same graph.
For the first infusion for times t> T^:






and S = — —
V 3 (a-B)
3
For the second infusion for times t (where
1 > V =
where R
C2t = R'e a(t T2) + s'e e(t-T2)
k '(a-k21)(l-e"a(T2"Tl))





a STYLISED SEMILOGARITHMIC PLOT OF DRUG CONCENTRATION .v. TIME AFTER
_
AN INFUSION GIVEN AT TWO DIFFERENT RATES
b SUPERIMPOSED SEMILOGARITHMIC PLOTS OF DRUG CONCENTRATION .v. TIME
AS A RESULT OF TWO SEPARATE INFUSIONS GIVEN AT DIFFERENT RATES
GLOSSARY OF SYMBOLS USED IN THE DERIVATION OF THE FORMULA TO OBTAIN
CORRECTED A & B VALUES FROM DRUG CONCENTRATION DATA OBTAINED FROM AN
INFUSION GIVEN AT TWO DIFFERENT RATES
T^ & T^ = Times to the end of the first and second infusions (min)
C = Blood drug concentration (yg ml-l)
kQ = First infusion rate (mg min-"-)
k0' = Second infusion rate (mg min-l)
A' & B' = Calculated intercept values of the a & 3 phases respectively-
after the combined infusion (yg ml--'-)
R & S = Hypothetical intercept values at T^ of the a &B phases
of the first infusion curve (yg ml--'-)
R' 8c S' = Hypothetical intercept values at T2 of the a 8c 0 phases
of the second infusion curve (yg ml~l)
t = Time after the end of the infusion (min)
XQ = The total dose of drug administered (mg)
■*» /3, k10, k2i, k^2 & Vc are as previously defined in Section 1
63,
and S' =
V (k21-3)(1-e 3(T2 Tl))
Vc3(a-3)
so combining 1 and 4 where C-^ + C2 = C then:
C = Re-a^t-Tl^ + R'e-01 ^t-T2^ + Se~^t-Tl^ + s,e~^^t~'1'2^ 7
when t = T2 then:
C = Re~a ^T2~t1 ) + R'e-01^0^ + Se~3^T2~Tl) + s'e~3^
so:
C = Re a (T2 Ti> + r' + se 3 Tl^ + S*
At the termination of the infusion at t = T,
c = a'e~a(t-T2) + B'e"3(t~T2) 10
as t-T9 = 0, then at t = T9, C = A' + B' 11
where A* = Re a^T2 Tl) + r* 12
and B' = Se 3 (T2 Tl) + S' 13
Substituting equations 2 and 5 in 12 for R and R' then;
A' =
ko(ct"k21) (1_e aTl)-e a(T2 Tl)
Vcct (a-g)






Vca (a-g) ko(l-e-c'Tl).e-o(,r2-Tll + ko'(l-e-0,(T2-Tl)
a-k21I _ J~A' =
Vca(a-g)
k .e-a(T2-Tl) - k e-aTl.e"a(T2-Tl)
o o
+ k ■ - k •.e a(T2"Ti)
o o
Also substituting equations 3 and 6 in 13 for S and S'
then:




k .e"^T2-Ti) _ k .e-3T1>e-g(T2-Tl)
o o
+ k ■ - k •.e-6<T2-Tl>"
o o
At this point it is necessary to substitute actual data
into the equations:
eg dog 7 . kQ = 4 mg min 1
k ' = 1.6 mg min
o
a = 0.0803 min ^
g = 0.0089 min





T2~T1 = 80 rain
A1 = 1.15 yg ml"1
B" =1.14 yg ml 1
So equation 14 becomes:
1.15 = [4.1
(0.0803-k21)
-0.0803.80 . -0.0803.20 -0.0803.80
. e - 4 . e . e

















0.00659 Vc = 0.1287-1.6026k21 17










1.96 - 1.64 + 1.6 - 0.785
(k„.-0.0089)









= 0.1287 - 1.6026k
21
0.00748k21 - 0.0000666 = 0.0000933 - 0.00116k21
0.00748k21 + 0.00116k21 = 0.0000933 + 0.0000666
k2^ = 0.0185 min
k-. „ = 5L§_ — 0.0386 min ^10
21






0.000725 V = 1.135k0,-0.0101C 21 19
Substituting the value for k21 into 16 then:
„ _ 0.1287-(1.6026 x 0.0185) _ 0.09905
c 0.00659 0.00659
V = 15.0 1
c







i ~ —1 _ 2.0012.00 yg ml B = j Q7 1.87 yg ml
-1
A B 12.00 1.87
Cap 0.0803 0.0089
As mentioned previously, the right atrial blood
samples of dogs 1, 2 and 3 have not been considered as
mixed venous blood, so the comparison of the pharmaco¬
kinetic variables of prilocaine in mixed venous and
arterial blood has been restricted to the results
obtained from dogs 4, 5 and 6 (Table 4-6). The complete
pharmacokinetic data from all six experiments can be
found in Appendix 15.
The calculated values for area under the curve
(AUCC) showed some difference from the measured values
(AUC^) with the AUCC values for both arterial and mixed
venous blood samples consistently less than the
corresponding AUCM values. Nevertheless, a two compart¬
ment open model and the derivation of the A and B values
appear to fit the data sufficiently well.
TABLE 4-6
PHARMACOKINETIC VARIABLES OF PRILOCAINE FOR DOGS 5, 6 AND 7
(mean data ± SD)
Mixed Venous Arterial
X SD X SD
a (min ) 0.081 0.003 0.089 0.008
6 (min "*") 0.0081 0.0013 0.0086 0.0009
t^a (min) 8.5 0.3 7.9 0.7
t*j3 (min) 88 15 81 9
A (tig ml ) 13.91 1.61 16.61 3.34
B (yg ml 1) 1.72 0.56 1.86 0.56
AUCC (yg ml ^.min ) 381 46 406 78
AUC (yg ml ''".min )
M
459 85 457 21
Clc (ml min 1 kg ) 43.9 6.1 42.0 3.4
Clw (ml min 1 kg )M 36.6 3.8 36.8 3.9
CI (ml min 1 kg )
ss
42.7 4.0 43.6 2.9
VB (1 kg 1) 4.6 0.9 4.4 0.7
V (1 kg"1)
Q
1.1 0.3 0.9 0.2
Vp (1 kg"1)
k1Q (min 1)
3.6 1.1 3.4 0.8
0.040 0.006 0.046 0.009
k21 (min 1) 0.016 0.004 0.017 0.003
k12 (min 1) 0.032 O.OOl 0.034 0.002
Individual data are given in Appendix 15
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To further check the validity of the analysis, a
computer predicted drug concentration/time profile was
created and the data generated subjected to the same
analysis as the experimental data.
The program used was SIMULA (in Fortran 4), run
on a Burrough's 6900 computer, with a capability of
handling up to a three compartment model and several
different infusion rates.
The input data required for the computer program
were values of V , k2^, k^2 and k^Q. These values were
chosen to be in the same order as the previously
calculated experimental data. The two infusion rates
were the same as used in the experiment, ie
kQ = 4 mg min and k ' =1.6 mg min ^.
The computer predicted drug concentration data
(Fig 4-3) was found to be very similar to the experimental
prilocaine concentration data. This data was subjected
to pharmacokinetic analysis on the basis of a two compart¬
ment open model under the same procedure as used for the
experimental data. A comparison of the data fed into the
computer program and the data obtained from the pharmaco¬
kinetic analysis of the predicted prilocaine concentration
data is shown in Table 4-7. The close agreement to these
data and the similarity between the AUCC and AUCM values
confirms the validity of the formula for the derivation
of the corrected A and B intercept values for an
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TABLE 4-7
A COMPARISON OF THE PHARMACOKINETIC DATA USED IN THE
SIMULA PROGRAM TO PRODUCE THE PREDICTED PRILOCAINE
CONCENTRATION DATA AND THE PHARMACOKINETIC DATA
CALCULATED FROM THIS CONCENTRATION DATA
Computer Calculated
Data Data
k21 (min 1) 0.018 0.019
k (min 1) 0.044 0.049
k12 (min 1) 0.032 0.037
vc (i) H to • 00 11.4
a (min ) 0.O84 0.095
3 (min "S 0.0095 0.0099
AUCC (yg ml .min ) 372
AUC (yg ml ^".min )M 362
A (yg ml 1) 16.21
B (yg ml 1) 1.99
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As can be seen from Table 4-6, the results of
pharmacokinetic analysis of both arterial and venous
blood samples are very similar and comparable to the human
pharmacokinetic data discussed earlier (Table 1-2). The
half life of elimination values of 88 min (mixed venous)
and 81 min (arterial) were shorter than the value of
97 min obtained for human volunteers. The volumes of
distribution obtained were 4.6 1 kg ^ (mixed venous) and
4.4 1 kg 1 (arterial) and these values were comparable to
the values of 4.9 1 kg ^ in humans, with the volumes
similarly divided between the central and peripheral
compartments in all cases.
As mentioned previously, there is some difference
between the AUC^ and AUCC values, hence the differences
between the Cl_, and CI., values. CI was calculated usingC M ss 3
k
the formula CI = using the mean C values from
ss C
„ ^ ssss
60-100 min. The resulting CI values were overestimated^ ss
since steady state had not been fully established during
this 60-100 min time period. The values that will be
discussed here are the Cl„ values of 36.6 ml min 1 kg ^M 3
(mixed venous) and 36.8 ml min ^ kg (arterial). When
compared with the human data of 35.5 ml min 1 kg ^ it
would appear that there was a close agreement of data.
However, reported values for hepatic blood flow in
various species of anaesthetised dogs vary from
31 ml min ^ kg ^ (Greenway & Stark, 1971) to 44 ml min ^
kg ^ (Teramoto & Schumacher, 1962). Ketterer et al (1960)
70,
using a similar anaesthetic technique as used in this study
reported the hepatic blood flow of the dog as 38 ml min
kg When compared to the liver blood flow in man of
only 24 ml min kg ^ (from Price et al, 1960; and the
mean weight of the volunteers in the human study of 70 kg)
it is apparent that although the clearance of prilocaine
in human volunteers is much greater than liver blood flow
with a ratio r- clearance ^ 1.5, this is not thehepatic blood flow '
clfisranc 8
case in the dog, where the ratio r -r-. r-= 3—33 was 1.hepatic blood flow
As previously stated, all animals were acidotic throughout
the experiments but fitting the pH and PCO2 data to the
nomogram produced by Carson et al (1965) showed that
cardiac output would have been maintained at normal
levels (± 10%). The animals had also experienced some
surgical trauma with the insertion of the catheters and
this factor was likely to have reduced the hepatic blood
flow. It is unlikely however that the hepatic extraction
of prilocaine would be 100% and hence it is possible that
there is extra-hepatic metabolism in the dog. Tucker et
al (1977) showed that hepatic blood flow in human
volunteers increased during prolonged infusion of ligno-
caine, etidocaine and bupivacaine therefore it is possible
that this tendency to increase hepatic blood flow would
be counteracted by the effect of trauma tending to
decrease the flow.
HEPATIC EXTRACTION OF PRILOCAINE IN ANAESTHETISED DOGS
INTRODUCTION
The previous dog experiments had shown that the
total body clearance of prilocaine was equal to hepatic
blood flow with little or no indication of pulmonary
metabolism occurring. Thus, if hepatic extraction of
prilocaine in the dog was 100% then liver metabolism of
this drug could account for the total body clearance.
Hepatic extraction data for the other amide type local
anaesthetics in humans (Tucker et al, 1977) had shown
that none of these drugs had an extraction value of
greater than 75% (etidocaine 73%, lignocaine 68% and
bupivacaine 37%).
This experiment was designed to determine the
hepatic extraction of prilocaine in the anaesthetised
dog and to determine what proportion of the total body
clearance was due to extra-hepatic metabolism.
MATERIALS AND METHODS
The Animals and Anaesthesia
Three mongrel dogs (Centre for Laboratory Animals,
Bush Estate, Edinburgh, GB) in the weight range 14-17 kg
were used in this experiment. Having been fasted over¬
night, the animals were premedicated with atropine
(0.6 mg), given intramuscularly (approximately 1 hr
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before the induction of anaesthesia), and then anaes¬
thetised with pentobarbitone sodium given intravenously
(25 mg kg ^). Endotracheal intubation was performed
and anaesthesia maintained by an infusion of pento¬
barbitone sodium (4 mg kg 1 hr into the left femoral
vein. The animals were ventilated (Harvard Animal
Respirator, Harvard Apparatus, Millis, Mass, USA) with
air, at a rate previously determined to maintain normal
blood gas status.
The Preparation
As stated above, the left femoral vein was
catheterised for the infusion of pentobarbitone sodium to
maintain anaesthesia. The left femoral artery was
catheterised to monitor blood pressure, using a Sanborn
pressure transducer (Hewlett Packard Ltd, South Queens-
ferry, West Lothian, GB) and a calibrated chart recording
of arterial waveform, as well as the ECG, were made. The
right femoral artery was catheterised for the sampling of
arterial blood, then a radio-opaque catheter inserted
into the right femoral vein for later positioning in the
hepatic vein.
To catheterise the portal vein and to position the
hepatic venous catheter, the abdomen was opened by a
midline incision extending from the bottom of the sternum
for approximately 40 cm. A tributary of the portal vein
was identified and a radio-opaque catheter passed through
the tributary and into the portal vein. The catheter was
tied firmly in position, with the tip of the catheter
located at a point before the vein merged with the liver
tissue. With the abdomen open, the radio-opaque catheter
in the right femoral vein was positioned in the hepatic
vein using an image intensifier to locate the tip of the
catheter.
The abdomen was closed and sutured and a vein in
the left forepaw of the animal (left cephalic vein) was
cannulated (Medicut, 18-G, Sherwood Medical Industries,
Ballymoney, Co Antrim, N Ireland) for the infusion of
prilocaine hydrochloride.
All catheters, unless otherwise stated, were Portex,
1.2 mm internal diameter, polyethylene catheters (Portex
Ltd, Hythe, Kent, GB). The positioning of the catheters
was checked by autopsy at the end of each experiment.
The Infusion
All three dogs received a 15 min infusion of
prilocaine hydrochloride. The infusion dose was 10 mg kg
prepared from 1% Citanest (Astra Chemicals Ltd, Watford,
GB) diluted in Hartmann's Solution (Compound Sodium
Lactate BP, Travenol Laboratories Ltd, Thetford, Norfolk,
GB) to obtain the correct dose in 30 ml. The infusion
was given into a vein of the left forepaw at a rate of
2 ml min using a Sage syringe infusion pump (Model 355,
Orion Research Inc, Cambridge, Mass, USA).
74.
The Samples
Blood samples (3 ml) were withdrawn simultaneously
from the femoral artery, the hepatic vein and the portal
vein at: 0, 5, 10, 15, 21, 30, 40, 70, 120 and 180 min.
Additional samples were withdrawn from the portal vein
at 17, 19, 23, 25, 55, 90, 150, 210 and 240 min. The
samples were transferred to 10 ml plastic lithium
heparin tubes (Brunswick, Sherwood Medical Industries)
and stored frozen until assayed for the whole blood
prilocaine hydrochloride content using a gas liquid
chromatographic technique as described in Appendix 1.
Blood loss was replaced with heparinised Hartmann's
Solution (10 units heparin ml "*") which also served to
keep the catheters patent.
The whole blood prilocaine concentration data
obtained from the portal venous samples was subjected to
pharmacokinetic analysis on the basis of a two compartment
open model as described in Section 1. The drug concen¬
tration data from all the sampling sites was combined to
determine the hepatic extraction of prilocaine by the dog.
RESULTS AND DISCUSSION
Heart Rate and Blood Pressure (Appendix 16)
There was a mean decrease in both systolic and
diastolic blood pressure of 17 mm Hg over the period of
the infusion from initial values of 181 and 132 mm Hg
respectively. This downward trend continued to the end
of the experiment at which time the systolic pressure had
decreased by 35 mm Hg and the diastolic pressure by
27 mm Hg.
The heart rate remained fairly constant throughout
the infusion period in all dogs. By the end of the
experiment there had been a mean reduction in heart rate
of 12 beat min ^ from the initial rate of 159 beat
min ^.
Prilocaine Concentration Data
At all sampling times during the infusion, the
arterial concentrations were greater than the portal
venous concentrations. The mean peak concentrations
obtained from all three sampling sites at 15 min were
13.46 yg ml (arterial), 9.92 yg ml ^ (portal venous)
and 4.78 yg ml (hepatic venous) (Table 4-8). After
terminating the infusion, prilocaine concentrations fell
rapidly at all sampling sites (Fig 4-4) with the
arterial concentrations generally less than the portal
venous concentrations. There then followed a slower
decrease in concentrations until the end of the experiment.
Hepatic venous prilocaine concentrations were less than
both arterial and portal venous concentrations at all
times, both during and after the infusion, and with dog 10






















WHOLE BLOOD PRILOCAINE HYDROCHLORIDE CONCENTRATION
DATA (yg ml-1) IN PORTAL VENOUS (PV) , HEPATIC
VENOUS (HV) AND FEMORAL ARTERIAL (A) SAMPLES











































Individual data are given in Appendix 17
FIGURE4-4
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Pharmacokinetic Data
The results obtained from the analysis of the portal
venous prilocaine concentration data (Table 4-9) were
similar to the data of the previous dog study (Table 4-6).
In this study, the AUCC and values were very similar
suggesting that the other calculated data were correct.
The half life of elimination of 71 min was somewhat
shorter than the previously obtained value of 88 min,
but the clearance values (C1M) °f 33.3 ml min ^ and
36.6 ml min ^ were very similar. The total volume of
distribution (V^) of 3.5 1 kg ^ was somewhat smaller than
the previously obtained value of 4.6 1 kg but the Vc
values in both experiments were very similar, ie
0.9 1 kg (this experiment) and 1.1 1 kg 1 (previous
experiment). It is apparent that this difference in V
.D
was due to a difference in the volume of distribution of
the peripheral compartment (V ).
The small differences seen here could however have
been due to alterations in the haemodynamic balance of
the dogs caused by the relatively extensive surgical
procedures required to insert the hepatic catheters.
Hepatic Extraction of Prilocaine
The percentage hepatic extraction was determined
from the equation:
TABLE 4-9
PHARMACOKINETIC VARIABLES OF PRILOCAINE FROM
PORTAL VENOUS SAMPLES OF DOGS 8, 9 AND 10
(mean data ± SD)
X SD
a (min "*") 0.069 0.008
g (min ) 0.0098 0.0006
t^a (min) lO.l 1.1
tbg (min) 71 4
AUCC (yg ml 1.min ) 300 72
AUC (yg ml ^.min )M 313 65
CI (ml min 1 kg ^) 33.3 6.2
VB (1 kg"1) 3.5 0.7
Vc (1 kg"1) 0.9 0.3
Vp (1 kg"1) 2.7 0.4
klQ (min 1) 0.043 0.006
k21 (min 1) 0.016 O.OOl
k12 (min 1) 0.020 0.005
Individual data are given in Appendix 18
where E = percentage hepatic extraction
HV = drug concentration in hepatic venous
sample
PV = drug concentration in portal venous
sample
and HA = drug concentration in hepatic arterial
sample (in this experiment, femoral
arterial sample)
The division of the input drug concentration into
%PV + 3HA is derived from data in Spector (1974) for the
relative supply of blood to the liver by the portal vein
and hepatic artery in thiopentone sodium anaesthetised
dogs.
The result of this analysis for all three
preparations are shown in Table 4-10. From this it can
be seen that there was very little variation throughout
the experimental period within each preparation but
there was marked interpreparation variability. The
overall mean hepatic extraction value of 59% for prilo-
caine is less than the values of 73% and 68% for etido-
caine and lignocaine respectively, reported by Tucker et
al (1977) in human volunteers. The reverse applies in
the case of bupivacaine which has been reported as
having a hepatic extraction of 55% in the dog (Irestedt
et al, 1976) as opposed to only 37% in humans (Tucker
et al, 1977).
TABLE 4-10
HEPATIC EXTRACTION OF PRILOCAINE IN DOGS






DOG 8 9 10 X SD
TIME (min)
5 47 23 90 53 34
10 48 33 81 54 25
15 58 38 85 60 24
21 65 37 76 59 20
30 67 41 76 61 18
40 59 38 80 59 21
70 55 41 87 61 24
120 61 27 86 58 30
180 61 30 100 64 35
X 58 34 85 59 26
SD 7 6 8 3
E = % hepatic extraction
HV = drug concentration in hepatic venous sample
PV = drug concentration in portal venous sample
HA = drug concentration in hepatic arterial sample
(in this experiment, femoral arterial sample)
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Using the hepatic blood flow of the dog reported
by Ketterer et al (1960) of 38 ml min kg ^ and the
mean hepatic extraction value of prilocaine determined
here (59%) , the clearance of prilocaine by the dog liver
was 22 ml min ^ kg ^. The mean total clearance of prilo¬
caine by these three preparations was 33 ml min ^ kg
implying that 11 ml min ^ kg (33%) of the total
clearance of prilocaine was extra-hepatic. From the
results of the previous dog experiments it seems unlikely
that the lungs could be responsible for this percentage
of extra-hepatic metabolism so it is probable that there
is another site of extra-hepatic prilocaine metabolism
in the dog.
SECTION 5
PHARMACOKINETICS OF PRILOCAINE IN NORMAL
AND ANEPHRIC ANAESTHETISED RABBITS
PHARMACOKINETICS OF PRILOCAINE IN ANAESTHETISED RABBITS
INTRODUCTION
The experiments with anaesthetised dogs had
indicated that although extra-hepatic metabolism of
prilocaine occurred there was no evidence of lung
metabolism of this drug.
Kidney slice incubations have been shown to meta-
o
bolise prilocaine (Geddes, 1965; Akerman et al, 1966a;
and this work, Section 3). The species chosen to
investigate the possible renal metabolism of prilocaine
was the rabbit and this study was designed to determine
the pharmacokinetics of prilocaine in the normal
anaesthetised rabbit prior to the investigation of
anephric preparations.
MATERIALS AND METHODS
The Animals and Anaesthesia
Three New Zealand White rabbits (mean weight 4.0 kg)
were used in this experiment. The animals were placed in
a restraining cage and an indwelling needle (Butterfly,
23-G, Abbot Laboratories Ltd, Queensborough, Kent, GB)
introduced into a vein in the dorsum of an ear through
which a 25% aqueous urethane solution (BDH Chemicals Ltd,
Poole, Dorset, GB) was injected slowly until complete
anaesthesia was obtained. Further doses of 25% urethane
were administered throughout the experiment to maintain
anaesthesia (total mean dose = 10.1 ml kg 1).
The Preparation
A tracheotomy was performed and a Portex T-adaptor
(Portex Ltd, Hythe, Kent, GB) used as a tracheotomy tube
The right jugular vein was dissected and a cannula
(Medicut, 21-G, Sherwood Medical Industries, Ballymoney,
Co Antrim, N Ireland) introduced into the vessel for the
infusion of prilocaine hydrochloride. The left jugular
vein and left carotid artery were also exposed and
similar cannulae introduced for the withdrawal of venous
and arterial blood samples. The cannulae were flushed
with heparinised 6% dextran (Molecular weight 70,000,
Pharmacia AB, Uppsala, Sweden) to maintain patency.
The Infusion
The prilocaine hydrochloride infusion of 10 mg kg
(prepared from Citanest, 0.5%, Astra Chemicals Ltd,
Watford, GB, diluted with saline to the appropriate
concentration) was given over a period of 15 min in a
volume of 7.5 ml using a Harvard syringe infusion pump
(Harvard Apparatus, Millis, Mass, USA) at a rate of
0.5 ml min ^.
The Samples
Blood samples (0.7 ml) were withdrawn from the
left jugular vein and left carotid artery simultaneously
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at the following times: 0, 5, 10, 15, 17, 19, 21, 25, 30,
40, 55, 70, 100, 130, 160, 190, 220 and 250 min. These
samples were stored in 1 ml EDTA tubes under refrigeration
until assayed for whole blood prilocaine hydrochloride
concentrations using the gas liquid chromatographic
technique described in Appendix 1.
The prilocaine concentration data was then subjected
to pharmacokinetic analysis on the basis of a two compart¬
ment open model as described previously (Section 1).
RESULTS AND DISCUSSION
Prilocaine Hydrochloride Concentration Data (Appendix 19)
During the infusion period, the arterial prilocaine
concentrations were much greater than the venous concen¬
trations as would be expected. The mean peak concen¬
tration for arterial samples was 6.26 yg ml ^ at 15 min
and for venous samples at the same time interval
3.36 yg ml ^. After the end of the infusion the arterial
prilocaine concentrations fell more rapidly than the
venous concentrations but in two of the three preparations
(nos 1 and 3; Figure 5-1) there was a temporary increase
in the arterial concentrations 25 min and 10 min
respectively after the end of the infusion.
Pharmacokinetic Analysis (Table 5-1)
The characteristics of the arterial prilocaine
concentration data of the rapid redistribution phase of
FIGURE 5-1
INDIVIDUAL SEMILOGARITHMIC PLOTS OF PRILOCAINE BLOOD CONCENTRATIONS
IN NORMAL ANAESTHETISED RABBITS AFTER INTRAVENOUS INFUSION .v. TIME
TABLE 5-1
PHARMACOKINETIC VARIABLES OF PRILOCAINE IN RABBITS
(mean data ± SD)
Venous Arterial
X SD X SD
a (min "S O.056 0.002 0.173 0.143
B (min 0.0055 0.0019 O.0054 0.0013
t^a (min) 12.4 0.4 5.9 3.5
t^B (min) 134 40 134 32
A (yg ml 1) 2.41 0.18 10.99 14.64
B (yg ml 1) 1.64 0.59 1.44 0.17
AUC^, (yg ml "'"•min ) 340 40 324 89
AUCw (yg ml "'".min )M 345 40 366 68
CI (ml min 1 kg "S 28.2 2.6 27.0 5.3
VB (1 kg"1) 5.6 1.8 5.9 1.2
V (1 kg 1)
c
2.4 0.5 1.8 1. 3
V (1 kg"1)
P
3.1 1.3 4.1 0.4
kio ^min ' 0.012 0.002 0.034 0.036
k (min 1) 0.025 0.004 0.031 0.006
k (min 1) 0.024 0.005 0.112 0.114
Individual data are given in Appendix 20
the drug, particularly in the first preparation,
resulted in quite large deviations in some of the
calculated arterial pharmacokinetic variables. However,
a comparison of the arterial and venous mean pharmaco¬
kinetic data showed them to be quite similar with little
difference between the AUC,„ values and, as a result of
this, the clearance values of 2 7.0 ml min-1 kg 1
(arterial) and 28.2 ml min ^ kg ^ (venous) were very
similar. These clearance values are much lower than the
values reported previously for unanaesthetised human
volunteers (35.5 ml min kg ^) and anaesthetised dogs
(36.6 ml min kg "*") . However, the liver blood flow of
unanaesthetised rabbits has been reported as 37 ml min ^
kg (White et al, 1967) and Wyler (1974) has reported
that in chlorolase-urethane anaesthetised rabbits,
liver blood flow is only 76% that of unanaesthetised
rabbits. Although these rabbits were anaesthetised with
urethane only, it is probable that the hepatic blood
flow could be about 28 ml min 1 kg . This would mean
that, as in the anaesthetised dog, clearance of prilo-
caine in the anaesthetised rabbit is virtually the same
as hepatic blood flow. As it is unlikely that the
hepatic extraction of prilocaine in the rabbit is 100%
it would appear that there is some degree of extra-
hepatic metabolism of prilocaine.
The mean values for the half life of elimination
at both sampling sites were identical (134 min). This
value exceeded the values from both the human volunteer
83.
(97 min) and dog studies (88 min). The main differences
between the pharmacokinetic variables obtained from venous
and arterial prilocaine concentration data were the a
values and hence the t^a values and also the k^ values,
this being due to the apparently very rapid redistribution
phase observed in the arterial concentration data. The
large difference between the values for the A intercepts
is due to a very high A value in one preparation only.
The mean V values differed between the two
c
sampling sites, being 2.4 1 kg from venous samples and
1.8 1 kg 1 from arterial samples. Both these values were
greater than the values for Vc found in either humans
(1.3 1 kg ^) or dogs (1.1 1 kg ^ mixed venous and
0.9 1 kg ^ arterial).
As the clearance data from these experiments, and
the tissue incubation data reported earlier, suggest
extra-hepatic prilocaine metabolism in the rabbit, it
was decided to examine further the fate of prilocaine
in the anaesthetised rabbit.
PHARMACOKINETICS OF PRILOCAINE IN
ANAESTHETISED ANEPHRIC RABBITS
INTRODUCTION
The results obtained from the previous rabbit
experiments had shown that the total body clearance of
prilocaine was approximately equal to the hepatic blood
flow. It was assumed that the hepatic extraction of
prilocaine in this preparation was less than 100% as had
been found in the dog (Section 4). It was therefore
proposed that if the kidneys of the rabbit were
metabolising prilocaine, then the total body clearance
of prilocaine in anephric preparations would be less
than in normal preparations. This experiment was
designed to test this hypothesis.
MATERIALS AND METHODS
The Animals and Anaesthesia
Four New Zealand White rabbits were used in this
experiment (mean weight = 2.4 kg). The anaesthetic
technique was as previously described in the study with
normal rabbits except that the mean dose of 25% urethane
was 8.1 ml kg .
The Preparation
The animals were prepared as described in the
preceding experiment with the following exceptions:
(1) there was no cannula in the left carotid artery;
(2) blood samples were taken only from the left jugular
vein, at the same time intervals as in the previous
experiment.
After the initial preparation, the kidneys were
exposed by opening the abdomen with a midline incision
and displacement of the intestines. The kidneys were
separated from the surrounding connective tissue and a
loop of string passed over each kidney. Each loop was
pulled tightly over the renal artery and vein to occlude
the renal blood circulation. The abdomen was closed and
prilocaine hydrochloride infused at 10 mg kg (as
previously described) for 15 min.
The Samples
0.7 ml blood samples were withdrawn from the left
jugular vein at the same time intervals as in the previous
experiment. The storage and analysis of the samples were
again as previously described.
Pharmacokinetic analysis of the prilocaine blood
concentration data was attempted by fitting this data to
a two compartment open model as has been previously
described in Section 1.
RESULTS AND DISCUSSION
Prilocaine Hydrochloride Concentration Data
The whole blood prilocaine concentration data was
not as expected. In both preparations 1 and 2, there
appeared to be little redistribution of the drug after
the end of the infusion (Fig 5-2) with the concentration
of the drug in the blood remaining at relatively high
levels, rabbit 2 having a concentration of 4.65 yg ml
at 130 min when it died. Rabbit 1 survived for the full
experimental period and at 250 min the venous prilocaine
concentrations had only fallen to 0.86 yg ml ^ compared
with 0.09 and 0.17 yg ml ^ in rabbits 3 and 4
respectively.
Pharmacokinetic Analysis (Table 5-2)
Although there appeared to be little evidence of
a redistribution phase in preparations 1 and 2, the
estimated half life of elimination values were 100 and
130 min respectively which are in the same order as the
t%(3 value obtained with the normal rabbits (134 min) .
Preparations 3 and 4 produced time concentration profiles
more typical of a two compartment open model (Fig 5-2)
with t%6 values of 68 min and 120 min respectively, the
former figure being much shorter than that found in the
normal preparations (134 min). The VD values for these
r5
preparations were greater than for normal rabbits,
apparently due to an increase of the values, with the
V values similar to the normal data. The values
c 10
FIGURE 5-2
INDIVIDUAL SEMILOGARITHMIC PLOTS OF PRILOCAINE BLOOD CONCENTRATIONS
IN ANEPHRIC ANAESTHETISED RABBITS AFTER INTRAVENOUS INFUSION .V. TIME
time (min)
TABLE 5-2
PHARMACOKINETIC VARIABLES OF PRILOCAINE HYDROCHLORIDE
IN ANEPHRIC ANAESTHETISED RABBITS
Preparation 3 4
A (yg ml 1) 3.59 3.38
B (yg ml 1) 0.97 0.70
AUCC (pg ml 1 .min ) 152 186
AUC (ng ml"1 min ) 153 205
Clc (ml min 1 kg 1) 65.3 53.8
Clw (ml min 1
M kg 1) 65.4 48.8
VB (1 kg"1) 6.4 8.4
Vc (1 kg"1) 2.2 2.5
Vp (1 kg"1) 4.2 5.9
k (min ) 0.030 0.021
k21 (min ) 0.022 0.014
k12 (min ) 0.022 0.023
t'sa (min) 10.9 13.7
t^B (min) 68 120
, . -1,a (min ) 0.064 0.052
B (min 1) 0.0102 0.0058
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were higher than the normal values in both preparations
(0.030 min 1 for 3 and 0.021 min 1 for 4, 0.012 min
for normal) suggesting a more rapid elimination of drug
from the body by the anephric preparations than the
normal preparations. This fact is confirmed by the very
high clearance values of the anephric preparations of
65.4 ml min ^ kg ^ (3) and 4 8.8 ml min kg (4) which
are approximately two times greater than the normal value
(28.2 ml min kg
It would appear from these results that an anephric
rabbit preparation is not a suitable technique to use in
assessing the role of the kidneys as a site of prilocaine
metabolism as this procedure appears to have an adverse
effect on the haemodynamic balance of the preparation.
In the case of preparations 1 and 2, it is probable that
the trauma of anaesthesia and surgery caused a collapse
of the circulation, particularly to the peripheral
tissues and the viscera and hence greatly reducing the
redistribution of the drug. In the case of preparations
3 and 4, it is possible that, with no adverse effects
caused by surgical trauma, the loss of the renal
circulation would cause 25% of the cardiac output, ie
that which had been supplying the renal circulation,
to be redistributed to other tissues. The most likely
site for redistribution of this increased blood flow
would be by dilation of the splanchnic blood vessels,
resulting in an increase in the overall hepatic blood
flow. This would be reflected by an increase in prilo-
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caine clearance. Bromage & Gertel (1972) reported that
the duration of brachial plexus blocks in patients with
chronic renal failure was shorter than in normal patients.
They stated that this could be due to increased cardiac
output in renal failure. However, Thompson et al (1971)
found no differences in pharmacokinetic variables of
lignocaine in normal patients and patients with renal
failure. Therefore, to look at possible renal metabolism
in the rabbit, an isolated perfused kidney preparation
would appear to be a more suitable technique.
SECTION 6
LUNG UPTAKE OF LIGNOCAINE AND PRILOCAINE
IN ANAESTHETISED HUMAN SUBJECTS
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FIRST PASS EFFECT OF THE HUMAN LUNG ON LIGNOCAINE
AND PRILOCAINE BLOOD CONCENTRATIONS
INTRODUCTION
Experiments with isolated perfused rat lungs (Section
2) had shown that lung tissue was capable of accumulating
large amounts of both lignocaine and prilocaine at steady
state perfusate concentrations. However, to protect the
brain from toxic concentrations of local anaesthetics,
lung tissue would be required to absorb large amounts of
these drugs on their first passage through this organ.
In experiments with anaesthetised pigs, it had been shown
that after an intravenous bolus injection of lignocaine,
the lungs could extract 44% of the administered dose on
a single passage through the pulmonary circulation
(Bertler et al, 1978). Using a similar technique with
unanaesthetised human volunteers, Jorfeldt et al (1979)
found a 60% extraction of lignocaine by the lungs.
This experiment was designed to compare the lung
uptake of prilocaine and lignocaine in humans on a single
passage through this organ after the simultaneous intra¬
venous administration of equal amounts of each drug.
MATERIALS AND METHODS
The protocol for this experiment was passed by the
Ethical Committee of the South Lothian District Division
of Anaesthesia.
Patients undergoing general anaesthesia for middle
ear surgery were studied. Radial artery cannulation
(Butterfly, 23-G, Abbot Laboratories, Queensborough,
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Kent, GB) for arterial blood pressure monitoring was a
routine procedure with these patients and this cannula
was used for the withdrawal of blood samples. Another
catheter (EZ 19-G, Deseret Pharmaceutical Co Inc, Sandy,
Utah, USA) was introduced into the ante-cubital vein of
the contralateral arm and advanced until it was judged
that the tip of the catheter was in a vein at the level
of the shoulder joint.
A mixture of 15 mg lignocaine hydrochloride mono-
hydrate (1.5 ml of 1% Lidothesin, Pharmaceutical
Manufacturing Co, Bolton, GB), 15 mg prilocaine hydro¬
chloride (1.5 ml of 1% Citanest, Astra Chemicals Ltd,
Watford, GB) and 5 mg indocyanine green (ICG) (Cardio
Green, Hynson, Westcott & Dunning, Baltimore, Maryland,
USA made up to 2.5 mg ml "*") , giving a total volume of
5 ml, was injected through the venous catheter over a
period of not more than 2 sec, immediately followed by an
injection of 10 ml saline to flush the catheter.
As the injection was made, continuous blood
sampling was commenced from the arterial cannula using a
peristaltic pump (Harvard Apparatus, Millis, Mass, USA).
For the first 90 sec period the rate of blood withdrawal
was approximately 20 ml min 1 and this was divided into
12 consecutive samples taken over 7.5 sec intervals. For
the next 30 sec the sampling rate was reduced to
approximately 10 ml min ^ and this was divided into two
samples taken over 15 sec intervals. The withdrawal rate
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was then reduced to approximately 5 ml min 1 for a further
period of 120 sec and this was divided into two samples
taken over 60 sec intervals.
The blood samples were collected into plastic lithium
heparin tubes (Brunswick, Sherwood Medical Industries,
Ballymoney, Co Antrim, N Ireland) and centrifuged as soon
as possible to obtain the plasma. The plasma samples were
analysed for ICG content using a spectrophotometric
technique and then each plasma sample remixed with its
corresponding red cell fraction and the whole blood
assayed for lignocaine hydrochloride monohydrate and
prilocaine hydrochloride using a gas liquid chromato¬
graphic technique (Appendix 1).
The experimental procedure was undertaken twice
with each subject. The first injection was made shortly
after induction of anaesthesia when it had been predicted
that the patient would be acidotic. The second injection
was made after the end of the operation and following a
period of hyperventilation of the patient which was
intended to move the patient's blood gas status towards
alkalosis.
Before each experiment, arterial blood samples were
withdrawn for blood gas analysis, determination of
haematocrit value (for the conversion of plasma ICG
concentrations to whole blood concentrations) and to
obtain normal plasma with which to calibrate the ICG
assay.
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Spectrophotometric Determination of ICG in Human Plasma
The instrument used was a Unicam SP 500 Spectro¬
photometer (Unicam Instruments Ltd, Edinburgh, GB).
The absorption of each sample was measured at a wavelength
of 805 nm using the null balance technique against a
blank plasma sample taken immediately before each
experiment. Due to the small volume of the samples, a
2 mm optical path length quartz cell with a total volume
of 0.8 ml was used.
Calibration curves were prepared from various samples
of normal plasma by spiking 1 ml aliquots of plasma with
microlitre quantities of 2.5 mg ml ICG solution.
Although the relationship between absorption and concen¬
tration was found to be linear up to 20 yg ml ^, there
were variations in the results obtained from different
subjects' plasma samples. As a result of this, a blood
sample was taken prior to each experiment and the plasma
from this used to perform a calibration curve for the
samples obtained from that experiment.
Because ICG is highly bound to plasma protein, of
which albumin is the principle carrier (95%), it was
necessary to determine the haematocrit value of each
subject's blood for each experiment to correct the
determined plasma ICG concentration to whole blood ICG
concentrations:
.-ri 1 , , , Plasma ICG Cone 0 .Whole blood ICG cone = x % plasma
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RESULTS AND DISCUSSION
The anticipated changes in the blood gas status
between the two separate experiments were not as marked
as had been expected. During the first run, four of the
five subjects studied could be regarded as being in an
acidotic state (Table 6-1), but in the second run only
two of the subjects had blood gases approaching a state
of alkalosis. Hyperventilation reduced the pCC^ values
in all subjects between runs one and two, but an increase
in pC>2 values occurred only in two of the five subjects.
The mean increase in pH between runs one and two was only
0.10 pH unit.
Initially, all blood concentrations of ICG were
multiplied by a factor of three to correct these values
for an injection of 15 mg of this drug, equivalent to the
dose of each local anaesthetic. The concentrations of
drug in the blood were compared by two methods. The
peak lignocaine and prilocaine concentrations were
expressed as a percentage of the peak ICG concentrations
(Table 6-2). In all cases these values were lower for
prilocaine than for lignocaine, with overall mean values
of 43% and 59% respectively, implying that prilocaine
was being retarded by the lungs to a greater extent than
lignocaine. With the exception of subject 1, the peak
blood concentrations of prilocaine were much lower than
those of lignocaine.
TABLE 6-1
blood gas analysis of arterial blood
RUN 1 RUN 2
Subject ^2 Pc°2 pH p°2 pco2 pH
(kPa) (kPa) (kPa) (kPa)
1 26.3 7.6 7.27 43.6 7.1 7.28
2 16.9 9.9 7.18 16.5 8.9 7.23
3 28.0 6.0 7.35 26.6 4.5 7.44
4 21.6 7.5 7.24 32.0 4.2 7.45
5 25.9 8.2 7.20 24.9 4.8 7.36
x 23.7 7.8 7.25 28.7 5.9 7.35
SD 4.5 1.4 0.67 10.0 2.0 0.97
TABLE 6-2
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The difference between the data for lignocaine and
prilocaine was statistically significant (p <0.001,
using Student's paired t test)
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Fig 6-1 shows blood drug concentration plotted
against time for both runs of one of the patients studied
(subject 2) and illustrates well the differences between
the three different drug concentrations throughout the
sampling period.
The areas under the drug concentration/time curves
(AUC) were measured up to the time when recirculation of
the ICG occurred, as judged from the shape of the ICG
concentration/time profile. Similar to the peak blood
concentration data, the AUC values for lignocaine and
prilocaine have been expressed as a percentage of the AUC
values for ICG (Table 6-3). The AUCs for prilocaine were
only 48% (overall mean value) of those for ICG with the
AUC values for lignocaine nearly 20% greater at 67%
(overall mean value).
As can be seen from both Tables 6-2 and 6-3 there
were no remarkable differences between the two experiments
with each subject which was not surprising, as there was
little change in the overall blood gas status between
experiments with any of the subjects studied.
ICG has been utilised as an inert marker by other
workers studying lung uptake of drugs. Davis & Wang
14
(1965) demonstrated a 33% removal of C -5-hydroxy-
tryptamine in dogs and Geddes et al (1978) found a 75%
14
first pass uptake of C -propranolol in man with a method
involving the simultaneous injection of ICG and drug.
Utilising a method similar to the one used in these
FIGURE 6-1
ICG, LIGNOCAINE AND PRILOCAINE BLOOD CONCENTRATIONS IN SUBJECT 2
AFTER INTRAVENOUS BOLUS INJECTION OF A MIXTURE OF THESE THREE DRUGS
( Run 1 - pH = 7.18; Run 2 - pH = 7.23 )
time (sec)
TABLE 6-3





















































The difference between the data for lignocaine and
prilocaine was statistically significant (p <0.001,
using Student's paired t test)
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experiments, Bertler et al (1978) showed a 44% first pass
uptake of lignocaine in anaesthetised pigs and using the
same technique Jorfeldt et al (1979) reported a 60% first
pass uptake of lignocaine in unanaesthetised volunteers.
The uptake of lignocaine reported here using the
method of AUC comparisons (33%) was less than the value
reported by Jorfeldt et al (60%). This may be due to the
fact that in this study the subjects were anaesthetised
and were receiving other drugs which could have inter¬
fered with the pulmonary uptake of the lignocaine. Also,
prilocaine was injected simultaneously with the lignocaine
and these two drugs were probably competing with each
other for the same uptake sites.
The mean reduction in the peak concentrations of
57% for prilocaine and 41% for lignocaine is likely to be
a significant factor in reducing the toxic effects of a
bolus injection of either of these local anaesthetics on
the central nervous system by reducing the tissue/blood
drug concentration gradient and hence reducing the amount
of drug the central nervous system tissue will absorb.
The greater lung absorption of prilocaine than lignocaine
in humans observed in this study is in agreement with the





The initial objectives of this study were to describe
the pharmacokinetics of prilocaine in man and thereafter
study the factors controlling the distribution and clearance
of the amide type local anaesthetics.
It is known that very small quantities of the amide
type local anaesthetics are excreted unchanged in the urine
and that the main site of metabolism of these drugs is in
the liver (Tucker et al, 1977). As a result of this, the
total body clearance values for these drugs are necessarily
less than hepatic blood flow. The results from the prilo¬
caine pharmacokinetic study in humans (Section 1) showed
the total body clearance of prilocaine (2.42 1 min "*") to
exceed the liver blood flow (1.7 1 min , Price et al,
1960). Published values for the urinary excretion of
prilocaine in human volunteer studies range from less than
1% (Mather, 1972 in Mather & Tucker, 1978) to approximately
6% in acidified urine (Boyes, 1967). The higher published
figure for the urinary excretion of prilocaine would still
leave over 20% of the clearance of prilocaine unaccounted
for, assuming the hepatic extraction of prilocaine to be
100%. Therefore, it was proposed that an extrahepatic site
of prilocaine metabolism existed.
Although prilocaine is the least lipid soluble of the
amide type local anaesthetics (Covino & Vassallo, 1976) it
was found to have a large volume of distribution in humans
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(343 1). Only etidocaine which is more than 100 times more
lipid soluble than prilocaine has a greater volume of
distribution (666 1). This large volume of distribution
and the high clearance of prilocaine were also found in the
dog and rabbit studies (Sections 4 and 5). There was little
interspecies variation in the volume of distribution data
when expressed in terms of body weight (1 kg 1). Using the
values derived from the venous prilocaine concentration
data, VD rabbit (5.6 1 kg "*") > human (4.9 1 kg > V_
£5 13 o
dog (4.6 1 kg 1). Similarly, the half lives of elimination
decreased in the order, t^8 rabbit (134 min) > t%6 human
(97 min) > t^3 dog (88 min). In the dog and rabbit studies,
where both arterial and venous blood samples were taken,
the differences between the pharmacokinetic variables derived
from the prilocaine concentration data of the two sampling
sites, were minimal. In the dog and rabbit studies, the
clearance of prilocaine was found to be approximately equal
to hepatic blood flow rather than exceeding it as had been
found in the human study. However, experiments to deter¬
mine the hepatic extraction of prilocaine in the dog
indicated that 33% of the total clearance of this drug was
extrahepatic (Section 4).
The greater total body clearance of prilocaine
compared to the other amide type local anaesthetics is
probably related to the method of its metabolic degradation.
It has been shown that for lignocaine which is a tertiary
amine, N-dealkylation is the initial metabolic step prior
to the hydrolysis of the amide bond (Hollunger, 1960a;
Boyes, 1967), whereas for prilocaine which is a secondary
amine, hydrolysis of the amide bond is the initial meta-
o
bolic reaction to occur (Geddes, 1965; Akerman et al,
1966a). Prilocaine has been shown to be more rapidly
metabolised than lignocaine in vivo (£kerman et al, 1966a)
suggesting that either the amidase responsible for the
hydrolysis of prilocaine is more available than the
enzyme responsible for the N-dealkylation of lignocaine or,
that the hydrolytic reaction is more facile than dealkylation.
Metabolism of prilocaine by lung and kidney slice
o
incubations was reported by Akerman et al (1966a) but no
lignocaine metabolism by these preparations was found.
Similarly, Post et al (1978) could not detect lignocaine
metabolism in lung slice preparations. The metabolism of
prilocaine by dog and rabbit lung and kidney slice
incubations has been confirmed (Section 3), but unlike the
previous work lung tissue appeared to have some capability
for lignocaine metabolism. These results, together with
the data obtained from the isolated perfused rat lung
preparations (Section 2), which indicated that large amounts
of prilocaine were accumulated by lung tissue, led to the
investigation of the lung as the site of extrahepatic meta¬
bolism. The lung seemed a more attractive choice than the
kidneys as the site of extrahepatic metabolism since it
receives the total cardiac output, thus requiring a much
lower extraction of the drug than would be necessary by the
kidneys.
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The in vivo work with dogs (Section 4) suggested that
little or no metabolism of prilocaine occurred in the
intact lung. A small significant decrease in steady state
blood prilocaine concentrations between pulmonary arterial
and aortic samples was found in two of the three
preparations studied, but this extraction of prilocaine
would not account for the extrahepatic metabolism of this
drug. It was shown that steady state blood prilocaine
concentrations had not quite been obtained during the
infusion and it is possible that the difference in concen¬
trations at the two sampling sites were a result of lung
uptake of the drug. Although this does not exclude the
possibility of pulmonary metabolism of prilocaine in
humans, it does nevertheless make it seem less likely.
To investigate the possibility of renal metabolism of
prilocaine, a comparison was made of the clearance values
in normal and anephric anaesthetised rabbits (Section 5).
The results showed that tying off the renal circulation
actually increased the clearance of prilocaine. This was
thought to have been caused by the fraction of the cardiac
output normally intended for the renal circulation being
redirected to the splanchnic circulation, thus increasing
the overall hepatic blood flow. This in turn would cause
an increase in the clearance of drug by the liver. The
possibility of renal metabolism remains to be investigated
further. It is unlikely that this could account for the
total extrahepatic metabolism of prilocaine in man, as the
renal extraction of prilocaine would need to be in excess
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of 100% if the hepatic extraction of this drug in man was
only 60%, as was found in dogs. Renal metabolism could
still account for some of the extrahepatic prilocaine
clearance and a study of this would probably be best
accomplished using an isolated perfused kidney preparation.
Other possible sites of prilocaine metabolism include
the gut, muscle and blood. It has been shown that prilo¬
caine is stable in human whole blood (Appendix 3), implying
that no metabolism occurred. To look for gut metabolism of
prilocaine, blood prilocaine concentration data is required
from the arterial supply to the gut and the venous system
draining it. This data was effectively generated in the
study of hepatic extraction of prilocaine in dogs, where
blood was sampled from the femoral artery and the portal
vein. If prilocaine was metabolised by the gut, then the
AUC value derived from the arterial blood drug concentration
data would be greater than the value derived from the portal
venous samples, as less drug would have reached the portal
vein. The AUC values obtained from the arterial and
portal venous prilocaine concentration data (Table 4-8)
gave very similar results (330 yg ml "'".min - arterial;
313 yg ml "'".min - portal venous) . Although the value
for the arterial data is 5% more than the portal venous
value, the arterial AUC is based on only nine data points
and the similarity between these two AUC values suggests
that the gut is not a site of extrahepatic metabolism.
There is no data to implicate muscle as a site of prilocaine
metabolism. The data presented here indicates that it is
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unlikely that there is an individual site of extrahepatic
prilocaine metabolism. It is possible then that this
extrahepatic clearance involves extremely low levels of
prilocaine metabolism in most of the body tissues. Hence,
the small pulmonary extraction of prilocaine at steady
state blood concentrations in the dog and the 5% difference
in arterial and portal venous AUC values may be part of a
widespread metabolism of prilocaine throughout the body.
Another explanation for the high clearance value
obtained for prilocaine is that this compound could be
highly bound in body tissues and released back into the
blood very slowly, so as to produce blood drug concen¬
trations less than the minimum detectable limit of the
assay. However, this period of drug release would have to
last several days to produce an AUC large enough to reduce
the clearance value to less than hepatic blood flow. It
thus seems unlikely that this occurs. Further work
remains to be done to elucidate the mechanisms involved in
the extrahepatic clearance of prilocaine.
The results of the pharmacokinetic study in humans
help to explain the low central nervous system toxicity
of prilocaine. Xstrom & Persson (1961) demonstrated that
prilocaine was less toxic than lignocaine in mice when
these drugs were administered by intravenous infusion.
Later, work with human volunteers (Eriksson et al, 1966)
showed prilocaine to be less toxic than lignocaine after
intravenous infusion of these drugs. Toxic reactions were
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evaluated by subjective symptoms, eg numbness of the lips
and tongue, auditory disturbances and drowsiness, and
also symptoms recorded by the experiment monitor, eg
slurred speech, ability to answer questions correctly and
muscular twitching. Again using intravenous infusions of
lignocaine and prilocaine in human volunteers, Eriksson &
Persson (1966) demonstrated that greater changes in human
electroencephalogram recordings occurred after the ligno¬
caine infusion than after the prilocaine infusion. These
differences can be explained by the higher clearance of
prilocaine than lignocaine in man (2.42 1 min 1 and 0.95
1 min respectively) and its larger volume of distribution
(343 1 and 212 1 respectively). A comparison of the Vc
values of prilocaine and lignocaine show a similar
difference. The V of prilocaine from the human volunteer
c c
study (Section 1) was found to be 1.3 1 kg ^, compared to
the value of 0.8 1 kg ^ for lignocaine (Boyes et al, 1971).
The Vc determined for mepivacaine in this work was also
0.8 1 kg 1. These factors will reduce blood concentrations
of prilocaine more rapidly than those of lignocaine and
thus the possibility of toxic concentrations of prilocaine
occurring will be reduced. Although a lower blood
concentration of prilocaine could mean a higher brain
o
tissue concentration, it has been shown by Akerman et al
(1966a) that, at the onset of local anaesthetic induced
convulsions, brain tissue concentrations of prilocaine were
two to three times greater than those of lignocaine.
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Another factor contributing to the low toxicity of
prilocaine is the ability of the lung to remove this drug
o
from the circulation. Akerman et al (1966a) found a
greater accumulation of prilocaine than lignocaine in lung
tissue of rats and this work has been verified by the
in vitro studies with rat lungs reported here (Section 2),
where prilocaine was found in concentrations two times
greater than those of lignocaine in lung tissue. A similar
lung uptake of these two compounds in anaesthetised human
subjects has also been demonstrated (Section 6). In each
subject studied, the blood concentrations of prilocaine
were consistently less than those of lignocaine after a
single passage through the pulmonary circulation. A
comparison with indocyanine green concentrations indicated
a reduction of possible peak concentrations of prilocaine
and lignocaine by 57% and 41% respectively. This implies
that after intravenous injection of these drugs, their
lung uptake will cause a significant reduction in the
blood concentrations reaching the brain, with those of
prilocaine approximately one third less than lignocaine
concentrations.
The greater lung uptake and volume of distribution
of prilocaine compared to lignocaine is difficult to
explain in terms of their physicochemical properties. The
lipid solubility of lignocaine is greater than that of
prilocaine (Covino & Vassallo, 1976) which suggests it
should be more readily taken up by body tissues. This
situation also occurs with the other amide type local
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anaesthetics. Post et al (1979) found that the
accumulation of three of these drugs by rat lung slice
incubations to be in the order bupivacaine > etidocaine >
lignocaine, although their order of lipid solubility is
etidocaine >> bupivacaine >> lignocaine. The effect of
the differences in the pKa values for these drugs was
nullified in these experiments by incubating the
preparations at different pH values to make the ratio of
uncharged base to cationic form of the drug equal in all
cases. The results of Post et al suggest that differences
in uptake may be related to the molecular structure of
these drugs. Fowler et al (1976) demonstrated that the
chain length of aliphatic amines was a determining factor
on the ability of lung tissue to absorb them. Using chain
lengths from C4 to C-^, a maximal lung uptake was found
with the Cr amine. Thus, the differences in the molecular
structures of the amide type local anaesthetics could be
a factor contributing to the differences in distribution
of these drugs.
Although lignocaine is bound to plasma protein to
a higher degree than prilocaine (64% and 55% respectively),
implying that more free prilocaine would be available for
uptake by tissues, this difference alone could not account
for the difference in lung uptake of these drugs.
As the lung significantly reduces the blood concen¬
tration of the amide type local anaesthetics reaching the
central nervous system, it is apparent that any factor
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which reduces the ability of the lung to perform this
function may lower the dose of drug required to produce
toxic effects. Lung fibrosis induced in rats has been
shown to impair lung accumulation of isoniazid and
dexamethasone (Gardiner et al, 1979) and it is probable
that other pulmonary diseases will have a similar effect
on lung uptake of drugs. The presence of other drugs has
been shown to interfere with lung uptake of local anaes¬
thetics, eg imipramine has been shown to displace lignocaine
from perfused rat lung preparations and both imipramine and
bupivacaine have been shown to inhibit accumulation of
lignocaine by rat lung slice preparations (Post et al,
1979) .
With the isolated perfused rat lung preparations
(Section 2) changing the pH of the perfusion medium appeared
to have no effect on the ability of the lung to accumulate
lignocaine. Other work on lung uptake of lignocaine,
bupivacaine and etidocaine with varying pH has produced
contrasting results. Post et al (1979) found a greater
lung tissue uptake of these three drugs at pH 8 than at
pH 7, using a tissue slice incubation technique. In vivo
II
work with rabbits (Sjostrand & Widman, 1973) demonstrated
much higher lung concentrations of bupivacaine in acidotic
animals than in normal animals after the intravenous
infusion of this compound. With the in vitro preparations,
the increase in the unionised form of the drug at alkaline
pH would mean that a greater proportion of the drug in the
incubation solution would be available for intracellular
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absorption. In the study with normal and acidotic rabbits,
the increase in lung concentrations of bupivacaine were
attributed to an increase in the overall blood drug concen¬
tration combined with an increase in the organ blood flow.
It was also suggested that in an acidotic state, changes
in the properties of the cellular membrane could occur and
the tissue affinity for bupivacaine increased.
A biphasic elimination of both prilocaine and ligno-
caine was observed with the in situ perfused rat lung
preparations (Section 2). A third phase of elimination was
seen with the higher doses of these drugs and attributed to
drug passing through the pulmonary circulation unaffected
by tissue uptake. The two phases of drug elimination from
the lung tissue were related to two different sites of
uptake for lignocaine and prilocaine. As the terminal
phase drug concentrations increased with dose, it was
proposed that the drug uptake associated with this phase
was dose dependent. The data suggested that as the dose
of the local anaesthetic increased, there was some
saturation of the sites of drug uptake. At all doses of
lignocaine and prilocaine, the terminal phase prilocaine
concentrations were significantly greater than those of
lignocaine, suggesting a higher initial tissue uptake of
prilocaine than lignocaine. These results are comparable
to those obtained by Post et al (1978) who demonstrated
that the uptake of lignocaine by isolated perfused rat lungs
was biphasic in nature. Also, Bertler et al (1978),
investigating lung uptake of lignocaine in pigs, found that
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at higher doses less of the total dose of drug was absorbed
by the lung, indicating saturation of uptake sites. It was
proposed by Post et al (1978) that the mechanisms involved
in the uptake of lignocaine were intracellular absorption
of the unionised form of the drug and binding of the
cationic form of the drug to negatively charged sites on
the pulmonary endothelial cell surfaces.
The ability of the lung to remove greater amounts of
prilocaine than lignocaine from the circulation was demon¬
strated in both the isolated rat lung preparations and in
the anaesthetised human studies. The peak concentrations
of prilocaine reaching the brain were found to be one third
less than those of lignocaine in human studies (Section 6)
and the much higher brain tissue concentrations of prilo¬
caine than lignocaine necessary to produce convulsions in
mice (Akerman et al, 1966a) suggest that prilocaine is less
likely to cause toxic reactions in clinical use than ligno¬
caine .
In conclusion, it seems that the lungs are functional
in absorbing large amounts of the amide type local anaes¬
thetics and play a major role in protecting the central
nervous system from toxic concentrations of these drugs.
Although it has been shown that lung tissue can metabolise
prilocaine in vitro, the intact organ appears to have little
or no capability for this metabolism. The high clearance
and volume of distribution of prilocaine found in man and
animals help to explain the low central nervous system
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GENERAL METHOD FOR GLC DETERMINATION OF PRILOCAINE
HYDROCHLORIDE AND LIGNOCAINE HYDROCHLORIDE MONOHYDRATE
IN RAT LUNG PERFUSATE AND HUMAN BLOOD (A)
GLC DETERMINATION OF PRILOCAINE HYDROCHLORIDE IN HUMAN
PLASMA (B), DOG BLOOD (B) AND RABBIT BLOOD (C)
Reagents
Lignocaine HC1 BP (Xylotox, Pharmaceutical Manufacturing Co,
Bolton, GB)
- 199 pg ml-"'" stock solution in 0.1 M HC1
Prilocaine HC1 (Citanest, Astra Pharmaceutical Products Inc,
Worcester, Mass, USA)
- 335 pg ml--*- stock solution in 0.1 M HC1
Methyl ethyl glycine xylidide HC1 (W36004 HC1, Astra Pharmaceutical
Products Inc)
- 193.7 pg ml stock solution in O.l M HC1
Dichloromethane (AnalaR grade, BDH Chemicals Ltd, Poole, Dorset, GB)
Sodium Hydroxide (AR grade, Koch Light Laboratories, Colbrook, GB)
- 5 M solution in distilled water
Tris (Tris (Hydroxymethyl) methylalanine, AnalaR grade, BDH Chemicals
Ltd)
- 2 M solution in distilled water
Absolute alcohol (AR Quality, James Burrough Ltd, London, GB)
Apparatus
10 pi Hamilton Syringe (Microliter No 701, Dyson Instruments,
Durham, GB)
11 ml capacity Quickfit round bottomed test tubes with ground glass
stoppers and Quickfit lO ml capacity conical centrifuge tubes
(Macfarlane Robson, Glasgow, GB)
Conical centrifuge tubes - 5 ml capacity (Macfarlane Robson, Glasgow,
GB)
Reciprocal test tube shaker (Townson & Mercer, Edinburgh, GB)
Vortex mixer (Gallenkamp, Glasgow, GB)
Heated water bath (Gallenkamp, Glasgow, GB)
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Chromatography
Instrument - Hewlett Packard Series 402 Gas Chromatograph (Hewlett
Packard, South Queensferry, West Lothian, GB)
Detector - Nitrogen selective (rubidium bromide crystal) flame
ionisation detector (Hewlett Packard, Model 15161A)
Column and Packing - 6 ft silanised glass U shaped column with an
internal diameter of 3/16 in. The column was
packed with 3% OV-17 on Chromosorb W-HP 80-100
mesh (Supelco, Canvey Island, Essex, GB) and
conditioned at 300°C for 24 hr with nitrogen
flowing through the column at approximately
10 ml min~l
Conditions
Oven temperature - 185°C (A), 205°C (B and C)
Flash heater temperature - 250°C
Flame detector temperature - 300°C
Helium (carrier gas) flow rate - 50 ml min ^
Hydrogen flow rate - 30 ml min ^
Air flow rate - approximately 300 ml min 1
Method (A and B)
To 2 ml of sample in an 11 ml test tube were added: 1 ml
aqueous W36004 HC1 solution (stock solution diluted to a concen¬
tration of 3.87 yg ml ^ with distilled water), 0.5 ml of 5 M sodium
hydroxide solution and 5 ml dichloromethane. The tubes were
stoppered and placed horizontally on the reciprocal shaker and
shaken for 15 minutes. The tubes were then centrifuged at approximately
g x 1200 to separate the aqueous and organic phases. The upper aqueous
layer was aspirated off and the remaining dichloromethane decanted into
the 10 ml conical centrifuge tubes. These tubes were placed in a
water bath at 45°C in a fume cupboard to evaporate off all the
dichloromethane. The samples were reconstituted in 20 yl absolute
alcohol and 1-4 yl aliquots injected into the gas chromatograph.
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Method (C)
To 0.5 ml blood in a centrifuge tube were added: 100 yl of
aqueous W36004 HCl solution (stock solution diluted to 19.4 yg ml ^
in distilled water), 100 yl 2 M Tris solution and 1 ml dichloromethane.
The contents of the tube were mixed on a vortex mixer for 30 sec then
the tubes centrifuged at approximately g x 1200 for 15 min. The upper
aqueous phase was aspirated off and the remaining dichloromethane
decanted into another centrifuge tube. These tubes were placed in a
water bath at 45°C in a fume cupboard to evaporate off all the dichloro¬
methane. The samples were reconstituted in 10 yl absolute alcohol and
3-5 yl aliquots injected into the gas chromatograph.
Under the conditions previously stated, the retention times on
the column were:
A - W36004 - 8 min
prilocaine - 9.5 min
lignocaine - 11 min
B and C - W36004 - 5 min
prilocaine - 6 min
Chromatograms are shown in Figs A1 and A2.
Standard samples were prepared by 'spiking' 2 ml blank
perfusate/blood/plasma samples with microlitre quantities of the
prilocaine and/or lignocaine stock solutions and these samples run
through the appropriate extraction procedure as described above.
Standard samples were run with each set of samples analysed. Sample
concentrations of the drugs were calculated from the ratio of the peak
height of either prilocaine or lignocaine to the peak height of
W36004. Calibration curves were constructed from runs of standard
samples of perfusate/blood/plasma.
L = LIGNOCAINE P = PRILOCAINE I = W36004 S = SOLVENT
CHROMATOGRAMS OF LIGNOCAINE, PRILOCAINE AND W36004 AFTER
EXTRACTION FROM RAT LUNG PERFUSATE (X) AND HUMAN BLOOD (Y)
DRUG CONCENTRATIONS: LIGNOCAINE - 1.46 yg ml~^" (X) ; 3.00 yg ml~^
PRILOCAINE - 1.71 yg ml" (X) ; 2.47 yg ml
THERE WERE NO PEAKS IN BLANK PERFUSATE / BLOOD SAMPLES INTERFERING
WITH THE DRUG PEAKS
FIGURE A2
CHROMATOGRAMS OF PRILOCAINE AND W36004 AFTER EXTRACTION FROM DOG
BLOOD (X)> RABBIT BLOOD (Y) AND HUMAN PLASMA (Z)
S
s I
time (min) time (min)
time (min)
P = PRILOCAINE I = W36004 S = SOLVENT R = UNIDENTIFIED PEAK
FOUND IN MANY HUMAN BLOOD/PLASMA SAMPLES. THIS PEAK DID NOT
INTERFERE WITH OTHER DRUG PEAKS.
PRILOCAINE CONCENTRATIONS: 3.16 yg (X)
2.33 yg ml (Y)
3.55 yg ml (Z)
The mean, standard deviation and coefficient of variation for
series of standard samples were:
A. Rat Lung Perfusate
Standard Sample Concentration: Lignocaine 1.99 yg ml ^
Prilocaine 2.01 yg ml
Lignocaine: 2.03, 2.07, 2.01, 2.14, 1.85, 1.98, 1.97, 2.07, 2.13
1.89 (x = 2.01, SD = 0.10, CV = 5%)
Prilocaine: 2.11, 2.22, 2.08, 2.31, 1.99, 1.98, 1.98, 2.07, 2.11
1.92 (x = 2.08, SD = 0.12, CV = 6%)
A. Human Blood
Standard Sample Concentration: Lignocaine 1.99 yg ml ^
Prilocaine 2.01 yg ml 1
Lignocaine: 2.10, 1.76, 1.98, 1.91, 1.84, 1.91, 1.82
(x = 1.90, SD = 0.11, CV = 6%)
Prilocaine: 2.17, 2.00, 2.07, 1.93, 1.99, 2.13, 2.19
(x = 2.07, SD = 0.10, CV = 5%)
B. Human Plasma
Standard Sample Concentration: Prilocaine 2.68 yg ml ^
Prilocaine: 2.79, 2.62, 2.58, 2.48, 2.57, 2.60
(x = 2.61, SD = O.IO, CV = 4%)
B. Dog Blood
Standard Sample Concentration: Prilocaine 1.68 yg ml
Prilocaine: 1.65, 1.69, 1.76, 1.70, 1.73, 1.73, 1.74, 1.73, 1.71
1.76 (x = 1.72, SD = 0.03, CV = 2%)
C. Rabbit Blood
Standard Sample Concentration: Prilocaine 2.68 yg ml ^
Prilocaine: 2.50, 2.70, 2.38, 2.60, 2.57
(x = 2.55, SD = 0.12, CV = 5%)
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The drug concentrations were determined as yg ml prilocaine
hydrochloride or yg ml ^ lignocaine hydrochloride monohydrate.
Throughout this thesis, these terms have generally been referred to
as prilocaine or lignocaine concentrations.
GLC DETERMINATION OF MEPIVACAINE HYDROCHLORIDE IN HUMAN PLASMA
The method was essentially the same as for the determination of
prilocaine hydrochloride in human plasma.
The coefficient of variation for a series of standard samples
was ± 5% at a concentration of 1 yg ml \
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APPENDIX 2
DETERMINATION OF THE STABILITY OF PRILOCAINE WHEN FROZEN IN PLASMA
INTRODUCTION
As many of the plasma and blood samples gathered in the course
of these experiments were stored frozen, a check on the stability of
prilocaine in frozen plasma samples was undertaken.
METHOD
A lOO ml sample of plasma from the Regional Blood Transfusion
Service (Royal Infirmary of Edinburgh) was 'spiked' with 1 ml of
aqueous prilocaine hydrochloride solution to give a concentration of
3.35 yg ml . 3 ml aliquots of the plasma were transferred to 5 ml
plain plastic tubes and placed in a deep freeze at approximately -20°C.
Pairs of samples were analysed for prilocaine content at intervals for
seven months, with the analysis of the first pair of samples taking
place on the day of preparation of the samples and before they had
been frozen. The analytical technique used was the GLC method
described in Appendix 1.
RESULTS AND CONCLUSION
The mean prilocaine concentration in each pair of samples is
given below:
1 2 3 4 7
3.46 3.54 3.25 3.44 3.39
Although there is slight variation in the results, it would
appear that prilocaine is stable when frozen in plasma samples.
Time (months) 0




DETERMINATION OF THE STABILITY OF PRILOCAINE IN HUMAN BLOOD
INTRODUCTION
Unlike other amide type local anaesthetics, the primary
metabolic pathway of prilocaine is by hydrolysis (Geddes, 1965;
o
Akerman et al, 1966a and b). It is possible that hydrolytic
enzymes in the blood could initiate prilocaine metabolism and this
experiment was designed to see if this was true.
METHOD
Venous blood samples were withdrawn from two healthy male
subjects and transferred to lO ml plastic lithium heparin tubes
(Brunswick, Sherwood Medical Industries, Ballymoney, Co Antrim,
N Ireland). For each subject aliquots of 3 ml of blood were trans¬
ferred to 10 ml glass tubes and 'spiked' with microlitre quantities
of aqueous prilocaine hydrochloride solution to give a resultant
concentration of 1.12 pg ml \ Two tubes from each set were
immediately frozen and the remaining four tubes were placed in a
water bath at 37°C with a reciprocal shaker. After 30 minutes, two
more tubes from each set were removed from the water bath and frozen
then the remaining tubes removed and frozen after 60 minutes.
The blood was subsequently assayed for prilocaine content using
a GLC technique as described in Appendix 1.
RESULTS AND CONCLUSION
The mean prilocaine concentration data for each pair of samples
at the three time periods is given below:
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PRILOCAINE HYDROCHLORIDE CONCENTRATIONS IN BLOOD
(yg ml 1)
Time (min) O 30 60
Subject
1 1.06 1.04 1.06
2 1.21 1.18 1.22




DETERMINATION OF THE WHOLE BLOOD/PLASMA
PRILOCAINE CONCENTRATION RATIO
INTRODUCTION
When expressing drug concentration data, it is generally
important to indicate if the data refers to whole blood or plasma
concentrations. The distribution of a drug between the red blood
cells and plasma depends on the extent of plasma protein binding of
the drug. In the case of prilocaine, Covino & Vassallo (1976) quoted
the percentage plasma protein binding to be 55% and the whole blood/
plasma concentration ratio to be 1.0, suggesting that for prilocaine,
whole blood and plasma concentration data are interchangeable. This
experiment was designed to determine if this was in fact the case.
METHODS
Venous blood samples were withdrawn from two healthy male
subjects and transferred to 10 ml plastic lithium heparin tubes
(Brunswick, Sherwood Medical Industries, Ballymoney, Co Antrim,
N Ireland). Microlitre quantities of aqueous prilocaine hydrochloride
solution were added to 4 ml aliquots of the fresh blood in silanised
10 ml glass test tubes to give concentrations of 0.36, 1.78, 3.55 and
7.10 pg ml \ One sample at each concentration was prepared in both
subjects' blood. The blood samples were thoroughly mixed then 1 ml
of blood pipetted from the samples and the remaining 3 ml of blood
centrifuged to separate the plasma.
1 ml aliquots of the plasma and whole blood were assayed for
prilocaine using the GLC technique described in Appendix 1.
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RESULTS AND DISCUSSION

















results confirm that it is possible to interchange whole
and plasma prilocaine concentration data.
APPENDIX 5
HEART RATE AND BLOOD PRESSURE
HUMAN VOLUNTEER STUDY
(mean values ± SD)
Heart rate Systolic BP Diastolic BP
(beats min~l) (mm Hg) (mm Hg)
Time
(min) X
SD X SD X SD
PRILOCAINE INFUSION
-10 77 18 125 13 76 3
-5 74 14 122 14 72 6
O 73 12 127 15 75 9
5 73 14 128 9 81 2
10 72 12 126 12 79 7
12.5 73 12 12 7 13 81 8
15 72 12 126 13 79 13
20 70 12 125 12 78 11
25 68 13 126 11 77 13
30 71 12 122 13 78 8
40 68 12 125 10 79 4
MEPIVACAINE INFUSION
-10 76 5 124 6 71 7
-5 74 7 123 6 71 7
0 76 9 125 3 74 9
5 80 14 126 4 77 11
10 79 15 12 7 4 82 11
12.5 80 9 12 7 1 84 11
15 77 9 126 5 81 12
20 75 9 128 6 78 7
25 73 10 127 4 78 6
30 75 7 124 4 77 8
40 75 9 123 6 77 8
APPENDIX6











































































































































































































MEPIVACAINE HYDROCHLORIDE PLASMA CONCENTRATION DATA
HUMAN VOLUNTEER STUDY
SUBJECT HB GD DF AN DL X SE
TIME (min)
5 1.74 2.28 2.02 1.17 3.55 2.15 0.40
10 2.78 3.04 3.54 1.94 5.40 3.34 0.58
12.5 3.91 2.82 4.05 2.48 7.25 4.10 0.84
15 3.67 1.97 3.48 2.23 4.68 3.21 0.50
20 2 .60 1.68 2.64 2.31 4.26 2.70 0.43
25 2.49 1.33 2.60 2.04 3.22 2.34 0.31
30 1.69 1.07 2.24 1.78 3.05 1.97 0.33
40 1.92 0.93 2.13 1.53 2.33 1.77 0.25
60 2.47 0.87 1.87 1.43 2.24 1. 78 0.29
90 1.63 0.68 1.56 1.35 1.65 1.37 0.18
120 1.54 0.68 1. 30 l.Ol 1.46 1.20 0.16
240 0.86 0.18 0.68 0.64 0.69 0.61 0.11
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INDIVIDUAL PHARMACOKINETIC DATA FOR MEPIVACAINE AFTER INTRAVENOUS INFUSION
HUMAN VOLUNTEER STUDY
SUBJECT HB GD DF AN DL X ±SD
VARIABLE
a (min ) 0.136 0.169 0.128 0.074 0.100 0.121 0.036
3 (min "*") 0.0043 0.0084 0.0058 0.0045 0.0064 0.0059 0.0016
k (min 1) O.Oll 0.025 0.012 0.007 0.018 0.015 0.007
k21 (min 1) 0.056 0.057 0.065 0.045 0.035 0.052 0.012
k12 (min 1) 0.074 0.096 0.058 0.026 0.053 0.061 0.026
t^a (min) 5.1 4.1 5.4 9.4 6.9 6.2 2.1
t'sB (min) 162 83 120 154 108 125 32
A (yg ml 1) 3.60 3.04 2.80 1.28 6.66 3.48 1.98
B (yg ml 1) 2.28 1.31 2.54 • 03o 2.95 2.18 0.64
AUCC (yg ml "'".min ) 559 175 463 417 526 428 152
AUC (yg ml "'".min )
M
579 180 469 444 530 440 155
(1 min-1)
C .-1,-1.

















, i ~1 ir(ml mm kg )
0.43 1.39 0.53 0.56 0.47 0.68 0.40




104 170 93 133 74 115 38




43 57 47 81 26 51 20
0. 6 0.8 0.8 1.3 0.3 0.8 0.4




0.8 1.5 0.8 0.8 0.6 0.9 0.3
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Dissolved in 1 litre of distilled water
APPENDIX 11
TYRODES BUFFER
NaCl - 8.0 g
KC1 - 0.2 g
MgCl2 - 0.1 g
CaCl2.2H20 - 0.2 g
NaH2P04 - 0.05 g
NaHC03 - 1.0 g
Glucose - 1.0 g





















HEART RATE AND BLOOD PRESSURE IN DOGS
PULMONARY EXTRACTION OF PRILOCAINE
(mean values ± SD)
Heart rate Systolic BP Diastolic BP
(beats min~l) (mm Hg) (mm Hg)
X SD X SD X SD
159 22 104 11 76 16
163 23 105 9 79 15
163 21 109 12 82 17
164 22 114 21 85 21
157 21 105 32 76 29
153 23 106 29 75 31
150 22 110 24 81 23
151 20 113 24 83 23
150 19 119 16 86 16
150 19 116 19 83 19
150 18 116 19 86 21
147 16 119 22 90 23
144 11 119 21 91 21
143 11 118 23 91 21
141 11 120 23 93 20
142 13 123 26 98 25
APPENDIX13









































































































































































PRILOCAINE HYDROCHLORIDE BLOOD CONCENTRATION DATA
FOR DOGS 1, 2 AND 3
(yg ml-1)
DOG 1 DOG 2 DOG 3
TIME
(min)
ART MVART MV ART MV
20 3.60 3.09 4.29 2.14 5.49 8.30
40 2.26 2.21 2.37 1.32 3.55 5.70
60 2.35 2.35 2.45 1.48 3.69 5.59
62 2.40 2.33 2.50 1.64 3.66 5.93
64 2.41 2.23 2.45 1.46 3.76 5.58
66 2.40 2.19 2.48 X 3.75 5.31
68 2. 39 2.30 2.42 1.44 3.43 5.67
70 2.36 2.32 2.50 1.39 3.68 5.67
72 2.34 2.49 2.51 1.49 3.67 6.00
76 2.31 2.37 2.42 1.37 3.79 5.83
78 2.44 2.26 2.58 1.51 3.72 6.05
80 2.46 2.31 2.67 1.69 3.72 5.90
82 2.39 2.27 2.71 1.70 3.76 6.04
84 2.49 2.31 2.74 1.82 3.76 5.96
86 2.52 2.52 2.79 1.94 3.80 6.04
88 2.64 2.47 2.79 1.85 3.93 5.92
90 2.65 2.54 2.97 2.14 3.86 5.84
95 2.69 2.56 3.02 1.86 3.91 5.83
lOO 2.66 2.28 2.97 2.07 3.97 4.62
102 1.91 1.76 1.93 1.74 2.92 3.20
104 X 1.65 1.73 1.41 2.60 2.96
106 1.57 1.49 1.62 1.29 2.37 2.65
108 1.47 1.46 1.41 1.20 2.15 2.44
110 1.36 1.34 1.36 1.05 1.96 2.33
115 1.15 1.14 1.20 0.88 1.64 1.96
120 1.13 1.13 1.02 0.82 1.42 1.73
130 0.89 0.91 0.83 0.68 1.12 1.41
145 0.70 O.63 0.66 0.51 0.86 1.15
160 0.57 0.53 0.53 0.41 0.66 0.91
190 0.37 0.37 0.37 0.31 0.46 0.62





= Mixed venous concentrations























































































































































































































































































































































































































HEART RATE AND BLOOD PRESSURE IN DOGS
HEPATIC EXTRACTION OF PRILOCAINE










X SD X SD X SD
159 19 181 36 132 16
159 19 177 34 124 13
159 19 167 34 118 13
155 21 164 31 115 13
158 21 165 26 119 13
158 21 162 28 119 17
158 21 167 34 120 18
157 22 167 25 119 15
153 21 162 26 117 13
157 28 159 21 113 13
153 24 154 20 107 13
148 21 150 16 107 14
146 22 153 27 107 14
148 24 154 24 107 14
144 24 150 32 105 24




















































































































































INDIVIDUAL PHARMACOKINETIC DATA FOR PRILOCAINE
AFTER INTRAVENOUS INFUSION IN DOGS
DOG 8 9 10 X SD
VARIABLE
A (yg ml ) 16.09 12.09 7.53 11.90 4.28
B (yg ml "S 1.62 1.05 1.16 1.28 0.30
AUC^, (yg ml \min ) 378 286 237 300 72
AUC (yg ml 1.min )
M
383 301 255 313 65
Cl^ (ml min 1 kg ) 27.4 35.2 42.4 35.0 7.5
CI (ml min 1 kg 1)M 27.0 33.5 39.4 33.3 6.2
VB (1 kg"1) 2.9 3.4 4.3 3.5 0.7
Vc (1 kg"1) 0.6 0.8 1.2 0.9 O. 3
V (1 kg 1)
P
2.3 2.6 3.1 2.7 0.4
k (min ) 0.047 0.046 0.037 0.043 0.006
k21 (min 1) 0.016 0.015 0.017 0.016 O.OOl
k
2 (mm ) 0.026 0.015 0.020 0.020 0.005
(min) 75 67 71 71 3.8
t^a (min) 8.8 10.5 10.9 10.1 1.1
a (min 1) 0.076 0.066 0.063 0.069 0.008
8 (min 1) 0.0093 0.0104 0.0098 0.0098 0.0006
APPENDIX19































































































































































































INDIVIDUAL PHARMACOKINETIC DATA FOR PRILOCAINE
AFTER INTRAVENOUS INFUSION IN RABBITS
VENOUS SAMPLES
RABBIT 1 2 3 X SD
VARIABLE
A (yg ml 1) 2.58 2.22 2.43 2.41 0.18
B (yg ml"1) 2.31 1.38 1.22 1.64 0.59
AUC^ (yg ml 1.min ) 348 375 296 340 40
AUC (yg ml 1.min )M 345 385 305 345 40
Clc (ml min 1 kg 1) 27.2 26.7 32.1 28.7 3.0
CI (ml min 1 kg 1)M 27.4 26.0 31.1 28.2 2.6
VB (1 kg-1) 3.5 6.5 6.7 5.6 1.8
V (1 kg"1)
c
1.9 2.8 2.6 2.4 0.5
V (1 kg"1) 1.6 3.7 4.1 3.1 1.3
k (min 1) 0.014 O.OIO 0.012 0.012 0.002
k21 (min 1) 0.030 0.024 0.022 0.025 0.004
k12 (min 1) 0.018 0.027 0.027 0.024 0.005
t^a (min) Hto • CD 12.3 12.1 12.4 0.4
(min) 90 169 144 134 40
. . -1,a (min ) 0.054 0.056 0.057 0.056 0.002





RABBIT 1 2 3 X SD
VARIABLE
A (yg ml 1) 27.88 3.02 2.06 10.99 14.64
B (yg ml 1) 1.63 1.38 1.31 1.44 0.17
AUCC (yg ml ^".min ) 387 363 223 324 89
AUC (yg ml 1 .min )
M
410 401 288 366 68
Clc (ml min 1 kg 24.4 27.5 42.6 31.5 9.7
CI (ml min 1 kg ^")M 23.1 24.9 33.0 27.0 5.3
VB (1 kg"1) 4.5 6.7 6.4 5.9 1.2
V (1 kg"1)
c
0.3 2.3 2.8 1.8 1.3
V (1 kg"1)
P
4.2 4.4 3.6 4.1 0.4
k (min 1) 0.076 0.012 0.015 0.034 0.036
k (min 1) 0.024 0.034 0.035 0.031 0.006
k12 (min 1) 0.243 0.058 0.036 0.112 0.114
t^a (min) 2.0 6.9 8.7 5.9 3.5
t^3 (min) 130 167 104 134 32
a (min 1) 0.338 0.101 0.080 0.173 0.143
3 (min 1) 0.0054 0.0041 0.0067 0.0054 0.0013
APPENDIX 21
PRILOCAINE HYDROCHLORIDE BLOOD CONCENTRATION DATA
FOR ANEPHRIC ANAESTHETISED RABBITS
(tag ml 1)
RABBIT 1 2 3 4
TIME (min)
5 1.30 1.52 2.61
10 2.28 6.69 2.72 4.14
15 3.60 10.25 4.17
17 3.44 9.88 3.55 3.58
19 3.41 9.42 2.78 2.40
21 3.54 8.83 2.48 2.37
25 3.24 8.22 1.98 1.66
30 3.14 8.06 1.50 1.50
40 3.11 7.83 1.05 1.08
55 3.09 6.90 0.76 O. 82
70 2.98 6.61 0.60 0.67
loo 2.44 5.01 0.38 O. 39
130 1.73 4.63 0.27 0. 36
160 1.33 0.23 O. 33
190 1.06 0.14 0.21
220 0.93 0.10 0.22
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PHARMACOKINETIC AND CLINICAL PHARMACOLOGICAL
STUDIES WITH MEPIVACAINE AND PRILOCAINE
G. R. Arthur, D. H. T. Scott, R. N. Boyes and D. B. Scott
summary
The tolerance and pharmacokinetic properties of mepivacaine and prilocaine were compared
following i.v. infusion of 250 mg (0.88 and 0.97 mmol respectively) of each drug in five healthy
volunteers. Side-effects were minor and occurred in only two subjects during the infusion of mepi¬
vacaine. Plasma concentrations ofmepivacaine were greater in each subject than the corresponding
values for prilocaine. The elimination half-life of mepivacaine was generally longer than that for
prilocaine, whereas the total body clearance of prilocaine was consistently greater than the corre¬
sponding value for mepivacaine. For each subject the clearance of prilocaine substantially exceeded
normal heptic blood flow and therefore an extra-hepatic site of metabolism of prilocaine has been
postulated.
Many studies have been carried out, in both patients
and volunteers, in which the detailed pharmaco¬
kinetics of certain local anaesthetic agents have been
measured and attempts have been made to associate
blood or plasma concentrations with pharmacological
effects of these drugs (Boyes et al., 1971; Reynolds,
1971b; Scott, 1975). Although early clinical studies
suggested smaller blood concentrations and a more
rapid clearance for prilocaine than for lignocaine, a
more detailed evaluation of the pharmacokinetics of
prilocaine has not been carried out in man. Although
mepivacaine has been the subject of pharmacokinetic
evaluation (Reynolds, 1971a; Tucker and Mather,
1975) there has been no systematic evaluation of the
relationship between blood concentration of the drug
and its toxic side-effects. This current study compared
the pharmacokinetics and clinical effects of both
prilocaine and mepivacaine following i.v. adminis¬
tration in a group of volunteers.
methods
The study was approved by the appropriate hospital
ethics committee. After being informed in detail of
the experiments, five healthy males (age 24-35 yr)
consented to participate. On two occasions, separated
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Edinburgh EH3 9YW. D. H. T. Scott, m.b., ch.b.,
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Edinburgh EH3 9YW. R. N. Boyes, ph.d., Astra Clinical
Research, 65, Queen Street, Edinburgh EH2 4NA.
0007-0912, 79/060481-05 $01.00
by at least 7 days, each volunteer received, over
12.5 min, i.v. infusion of 250 mg of either mepi¬
vacaine HC1 (0.88 mmol) or prilocaine HC1 (0.97
mmol) in 50 ml saline. The experiment was carried
out in a double-blind manner and the infusions were
administered in a random sequence. Venous blood
samples were taken during the infusion and at
frequent intervals for 4 h thereafter. Systemic arterial
pressure was monitored during the course of the
experiment and the e.c.g. was tape-recorded con¬
tinuously for 50 min starting 10 min before com¬
mencing the infusions.
The venous blood samples were collected into
heparinized tubes, centrifuged, and the separated
plasma stored in a freezer until analysis. Plasma
concentrations (expressed as free base) of mepi¬
vacaine and prilocaine were determined using a gas
chromatographic procedure similar to that described
by Tucker (1970). Under the conditions employed
the minimum detectable limit for both drugs was
0.05 ug ml-1 and there was a coefficient ofvariation of
± 5% at a concentration of 1 ug ml-1.
The plasma concentrations of prilocaine and mepi¬
vacaine for each volunteer were subjected to manual
"curve stripping" and the resulting mathematical
constants were used for pharmacokinetic analysis (see
Appendix). From these data the elimination half-life
(T,), area under the plasma drug concentration curve
(AUCc) and total body clearance (F) of drug could
be derived. The area under the plasma concentration
curve was also measured geometrically (AUCm) as a
means of checking the pharmacokinetic calculations.
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Table I. Pharmacokinetic data for mepivacaine after i.v. infusion in five volunteers,
a is the slope of the rapid distribution phase of the drug; 0 is the slope of the slower elimination
phase of the drug; A and B the intercept values of the at and 0 phases on the plasma drug
concentration axis at time (t) = 0 (values corrected for infusion time—see Appendix, equations
(2) and (3)); 7"j the elimination half-life of the drug; AUCc and AUCm the calculated and
measured areas under the plasma drug concentration curve (see Appendix); V the total body
clearance of the drug from the body
Volunteer no.
1 2 3 4 5 Mean SD
oc (min-1) 0.136 0.169 0.128 0.074 0.100 0.101 (±0.066)
0 (min-1) 0.0043 0.0084 0.0058 0.0045 0.0064 0.0059 ( + 0.0016)
A (ug ml-1) 3.6 3.04 2.80 1.28 6.66 3.48 (±1.98)
B (ug ml-1) 2.28 1.31 2.54 1.80 2.95 2.18 (+ 0.64)
Tj (min) 162 83 120 154 108 125 (±32)
AUC,. 559 175 463 417 526 428 (±152)
(ug ml-1 min-1)
AUC,, 579 180 469 444 530 440 (±155)
(ug ml-1 min-1)
V (litre min-1) 0.45 1.43 0.54 0.60 0.48 0.70 (±0.41)
Table II. Pharmacokinetic data of prilocaine after i.v. infusiot,i in five volunteers
Volunteer no.
1 2 3 4 5 Mean SD
a (min-1) 0.080 0.105 0.364 0.061 0.105 0.143 (±0.125)
0 (min-1) 0.0052 0.0057 0.0107 0.146 0.0068 0.0086 ( + 0.0040)
A (;xg ml-1) 1.48 1.24 8.29 1.13 2.17 2.86 (+ 3.06)
B (rug ml-1) 0.39 0.37 0.77 0.84 0.58 0.59 ( + 0.21)
7'. (min) 134 122 65 43 102 93 (±38)
AUC,. 94 77 95 76 106 90 (±13)
(ug ml-1 min-1)
AUC,,, 97 74 114 71 94 90 (±18)
(ug ml-1 min-1)
V (litre min-1) 2.66 3.25 2.64 3.29 2.36 2.84 (±0.41)
RESULTS
No significant alterations in arterial pressure or e.c.g.
were observed during any of the infusions . The only
subjective signs of toxicity were noted by two of the
volunteers who reported numbness of the tongue and
slight lightheadedness during the infusion of mepi¬
vacaine.
The plasma concentrations of prilocaine were
substantially less than those of mepivacaine in all
instances (fig. 1). The relevant pharmacokinetic data
for each drug calculated from the plasma concen¬
tration data are summarized in tables I and II. The
elimination half-life data for the two drugs suggested
a more rapid decrease in plasma concentrations for
prilocaine. There was considerable intersubject
variability in these half-life data and, at least in
subject 2, the rate of elimination of mepivacaine
appeared to exceed the corresponding rate for prilo¬
caine. However, the total body clearance of prilocaine
was consistently greater than that ofmepivacaine and,
Fig. 1. Mean venous plasma concentrations of mepivacaine
(•) and prilocaine (A) after i.v. infusion of 250 mg of each
drug, on separate occasions, in five male volunteers.
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for each volunteer, the clearance value of prilocaine
was in excess of 2 litre min-1.
DISCUSSION
Local anaesthetic agents, in particular lignocaine and
bupivacaine, have been subject to extensive pharmaco¬
kinetic evaluation. Attempts have been made to
associate blood concentrations of these drugs with
their pharmacological side-effects (Boyes et al., 1971;
Reynolds, 1971b; Scott, 1975). Although early reports
suggested that prilocaine was less toxic than other
amide local anaesthetic agents and that plasma
concentrations were substantially smaller when equal
doses were administered, this drug has not been the
subject of a detailed pharmacokinetic evaluation. The
pharmacokinetics of mepivacaine has been reported
previously in volunteers (Reynolds, 1971a; Tucker and
Mather, 1975). It should be noted that the data for
this drug shown in table I compare well with those
reported previously by Tucker and Mather (1975).
For example, they reported a mean terminal half-life
of 114min and a clearance of 0.78 litre min-1, (in
seven subjects) compared with the values of 125 min
and 0.70 litre min 1 respectively in the present study.
The large clearance values for prilocaine shown in
table II are of particular interest. Not only are these
values approximately four times greater than those for
mepivacaine but also they exceed 2 litre min -1 in
each individual. Local anaesthetic drugs of the amide
type are usually considered to be metabolized almost
entirely by the liver. The mean value for hepatic
blood flow in a normal population is often taken to be
1.7 litre min "1 (Price et al., 1960)—less than all the
calculated clearance values for prilocaine in this study.
This large plasma clearance of prilocaine may be
explained by three possible mechanisms. First, all our
volunteers may have had inordinately great hepatic
blood flows. This explanation is unlikely because the
clearance values for mepivacaine are very similar to
those reported previously and if our volunteers were
unusual their clearance values would have been
greater. Second, AUCc, which was used as the de¬
nominator in the clearance calculation (Appendix,
equation 5), may have been underestimated because
blood sampling was terminated at 240 min. Prilo¬
caine taken up by tissues may have returned to the
general circulation only very slowly. This is unlikely
to be the complete explanation of the high calculated
clearance because in every instance virtually no drug
was detectable in the samples at 240 min. AUC
occurring after the initial 240-min measurement
period would have to equal 50-100° 0 of the AUC
during the first 4-h measurement period in order that
the clearance values be calculated at values equal to
or less than hepatic blood flow. Furthermore, there
was no indication that the slope of the plasma concen¬
tration curve was reducing as might be expected if
drug was being returned to the circulation from a
storage site. Third, it is possible that prilocaine
undergoes some degree of extra-hepatic metabolism.
In an early pharmacological evaluation Akerman and
others (1966) reported that prilocaine could be
metabolized by both lung and kidney slices from the
guineapig. It has been reported that prilocaine
metabolism is an anaerobic process not involving the
oxidative enzymes of the liver (Geddes, 1965;
Akerman et al., 1966). It is possible that the enzymes
responsible for this amide hydrolysis process are not
located exclusively in the liver. Because the lungs
receive the entire cardiac output, it is attractive to
speculate on this organ as a possible site of extra-
hepatic metabolism. It is necessary only to postulate a
very low extraction and metabolism of the drug by
lung tissue in order to account for clearance in excess
of hepatic flow. Further detailed experiments in
animals are necessary to elucidate the site and mecha¬
nism of this possible extra-hepatic metabolism. If the
lung is involved, the clinical implications could be
extensive. The possibility that the lung acts as a
buffer between the site of injection and the systemic
circulation, thereby reducing the toxicity of certain
local anaesthetic drugs, would be a specific example.
It is also noteworthy that in these experiments there
was little or no objective or subjective sign of toxicity
observed in any of the volunteers. This might be
expected with prilocaine. However, previous reports
have implied that the toxicity of mepivacaine was
comparable to that of lignocaine. If compared with a
previous study (Scott, 1975) in which lignocaine was
administered under similar conditions to a group of
volunteers (including four of the five subjects in the
present study), the current data would suggest that,
when administered i.v., mepivacaine may be less
toxic than lignocaine and that larger plasma concen¬
trations may be tolerated before side-effects are
observed. However, it should be noted that, as
previously reported by Tucker and Mather (1975),
the clearance of mepivacaine is less than that for
lignocaine. Therefore, there will be a greater tendency
for mepivacaine to accumulate following multiple
injections, as might occur in obstetric analgesia.
There are certain circumstances in clinical practice
in which high doses of local anaesthetic drug must
be given to ensure success. In addition, certain
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techniques involve injecting the drug i.v., for example
Bier's block. In such instances prilocaine would appear
to offer important advantages in terms of toxicity.
The drug is frequently rejected because it can cause
methaemoglobinaemia, but the consequences of this
are seldom of clinical importance and this disadvan¬




The plasma concentration-time relationships, after stop¬
ping the i.v. infusion, for both prilocaine and mepivacaine
were analysed using equation (1):
C1 = /l1e-a"+B1e-« (1)
where C1 = plasma concentration of the drug, a = the slope
of the rapid distribution phase of the drug, j3 = the slope of
the slower elimination phase of the drug, and A1 and B1
are the intercept values of the a and j3 phases on the plasma
drug concentration axis at time (t) = 0.
The values of A1 and B1 were corrected for the infusion
time using equations (2) and (3) (Loo and Riegelman,
1970):
A- aT ■A' (2)
1 — e-aT
where r = the infusion time and A and B are the corrected
intercept values.
The area under the plasma concentration curve (AUC) was
measured (AUC,n) using the trapezoidal rule and a correc¬
tion for infinite time (Gibaldi, 1977).
AUC was also calculated (AUCc) from the relationship:
AUCc = - +| (4)a p
AUCc was used to estimate the total body clearance of
each drug from the following equation (Gibaldi, 1977):
F. dose
Total clearance (V) = (5)
uCjq
Normally, it is assumed that F (the fraction of the drug
reaching the systemic circulation) equals 1 when drugs are
administered i.v.
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PHARMACOCINETIQUE ET ETUDES CLINQUES
PHARMACOLOGIQUES DE LA MEPIVACAINE
ET DE LA PRILOCAINE
RESUME
On a compare la tolerance et les proprietes pharmaco-
cinetiques de la mepivacaine et de la prilocaine, apres
infusion intraveineuse de 250 mg (0,88 et 0,97 mmol
respectivement) de chacun de ces medicaments a cinq
volontaires en bonne sante. Les effects secondaires ont ete
mineurs et ne se sont manifestos que sur deux sujets pendant
l'infusion de mepivacaine. Les concentrations de mepi¬
vacaine dans le plasma ont ete plus importantes, sur chaque
sujet, que les valeurs correspondantes pour la prilocaine.
La demi-vie d'elimination de la mepivacaine a en general
ete plus longue que celle applicable a la prilocaine, alors que
le coefficient d'epuration plasmatique total du corps,
applicable a la prilocaine, a ete constamment plus important
que le valeur correspondante applicable a la mepivacaine.
Pour chaque sujet, le coefficient d'epuration plasmatique
de la prilocaine a depasse d'une maniere substantielle le
debit sanguin hepatique normal et on a done postule un site




MIT MEDIVACAIN UND PRILOCAIN
ZUSAMMENFASSUNG
Nach intravenoser Infusion von 250 mg (0,88 bzw.
0,97 nmol) Mepivacain und Prilocain in fiinf gesunde
freiwillige Versuchspersonen wurden die Toleranz und
pharmakokinetischen Eigenschaften der beiden Drogen
verglichen. Nebenwirkungen waren geringfiigig und kamen
nur bei zwei Versuchspersonen wahrend der Mepivacainin-
fusion vor. Die Plasmakonzentrationen von Mepivacain
waren in alien Versuchspersonen grosser als die entsprechen-
den Werte fur Prilocain. Der Eliminationshalbwert war
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allgemein grosser fur Mepivacain, als fur Prilocain,
wohingegen die Gesamt-Prilocainclearance des Korpers
konsistent hoher lag, als der entsprechende Wert fur
Mepivacain. Bei jeder Versuchsperson iiberschritt die
Prilocainclearance wesentlich den normalen hepatischen
Blutstrom und es wurde daher ein extra-hepatischer Situs





La tolerancia y las propiedades farmacocineticas de la
mepivacaina y de la prilocaina fueron comparadas tras la
infusion intravenosa de 250 mg (0,88 y 0,97 mmol,
respectivamente) de cada droga en cinco voluntaries sanos.
Los efectos colaterales fueron menores y solo se presentaron
en dos sujetos durante la infusion de mepivacaina. Las
concentraciones de plasma de mepivacaina eran mayores
en cada sujeto para con los valores correspondientes de la
prilocaina. El periodo de vida media de eliminacion de la
mepivacaina era mayor, en general, que el de la prilocaina,
mientras que la depuracion total de prilocaina en el cuerpo
era permanentemente mayor que el valor correspondiente
de la mepivacaina. Para cada sujeto, la depuracion de la
prilocaina excedia de manera apreciable el flujo sanguineo
hepatico normal y, por lo tanto, se postulo la existencia de
un punto extra-hepatico del metabolismo de la prilocaina.
